<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SUSTIVAÂ - efavirenzÂ tablet, film coatedÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use SUSTIVA safely and effectively. See full prescribing information for SUSTIVA.<br>Â 		<br>SUSTIVA<span class="Sup">Â®</span> (efavirenz) capsules for oral use<br>SUSTIVA<span class="Sup">Â®</span> (efavirenz) tablets for oral use<br>Initial U.S. Approval: 1998</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Dosage and Administration, AdultsÂ <a href="#Section_2.1">(2.1)</a>  Â Â Â 12/2011 </p>
<p class="Highlighta">Warnings and Precautions
								<br>Â Â Â Â Â Coadministration with Related ProductsÂ <a href="#Section_5.3">(5.3)</a>  Â Â Â 08/2012
								<br>Â Â Â Â Â RashÂ <a href="#Section_5.7">(5.7)</a>  Â Â Â 06/2012
								<br>Â Â Â Â Â Immune Reconstitution SyndromeÂ <a href="#Section_5.11">(5.11)</a>  Â Â Â 08/2012 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">SUSTIVA
is a non-nucleoside reverse transcriptase inhibitor indicated in combination
with other antiretroviral agents for the treatment of human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span>
virus type 1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.Â <a href="#Section_1"> (1)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul class="Disc">
<li>SUSTIVA should be taken orally once daily on an empty stomach, preferably
at bedtime.Â <a href="#Section_2"> (2)</a>
</li>
<li>Recommended adult dose: 600 mg.Â <a href="#Section_2.1"> (2.1)</a>
</li>
<li>With voriconazole, increase voriconazole maintenance dose to 400
mg every 12 hours and decrease SUSTIVA dose to 300 mg once daily using the
capsule formulation.Â <a href="#Section_2.1"> (2.1)</a>
</li>
<li>With rifampin, increase SUSTIVA dose to 800 mg once daily for patients weighing 50 kg or more.Â <a href="#Section_2.1"> (2.1)</a>
</li>
</ul>
<a name="i6fb3b5ca-fd50-446c-8662-546aa7120f5a"></a><table border="0" cellpadding="2" cellspacing="1" width="90%">
<colgroup>
<col width="13%">
<col width="13%">
<col width="13%">
<col width="01%">
<col width="13%">
<col width="13%">
<col width="13%">
</colgroup>
<tbody class="Headless">
<tr class="First"><td class="Lrule Rrule Toprule" colspan="7" rowspan="1">				Pediatric Patients at Least 3 Years and at Least 10 kg Â <a href="#Section_2.2"> (2.2)</a>
</td></tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">kg</td>
<td class="Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">lbs</td>
<td class="Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">dose</td>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">kg</td>
<td class="Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">lbs</td>
<td class="Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">dose</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">10
- &lt;15</td>
<td class="Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">22
- &lt;33</td>
<td class="Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">200
mg</td>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">25
- &lt;32.5</td>
<td class="Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">55
- &lt;71.5</td>
<td class="Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">350
mg</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">15
- &lt;20</td>
<td class="Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">33
- &lt;44</td>
<td class="Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">250
mg</td>
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">32.5
- &lt;40</td>
<td class="Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">71.5
- &lt;88</td>
<td class="Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">400
mg</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">20
- &lt;25</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">44
- &lt;55</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">300
mg</td>
<td class="Lrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">at
least 40</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">at
least 88</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="1" rowspan="1">600
mg</td>
</tr>
</tbody>
</table>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc">
<li>Capsules: 200 mg and 50 mg.  <a href="#Section_3"> (3)</a>
</li>
<li>Tablets: 600 mg.  <a href="#Section_3"> (3)</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>SUSTIVA is contraindicated in patients with previously demonstrated
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (eg, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, or toxic
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span>) to any of the components of this product.  <a href="#Section_4.1"> (4.1)</a>
</li>
<li>For some drugs, competition for CYP3A by efavirenz could result
in inhibition of their metabolism and create the potential for serious and/or
life-threatening adverse reactions (eg, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, prolonged sedation,
or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>).  <a href="#Section_4.2"> (4.2)</a>
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics">Do not use as a single agent </span>or add on as a sole
agent to a failing regimen. Consider potential for cross resistance when choosing
other agents.  <a href="#Section_5.2"> (5.2)</a>
</li>
<li>Not recommended with ATRIPLA, which contains efavirenz, emtricitabine,
and tenofovir disoproxil fumarate, unless needed for dose adjustment when coadministered with rifampin.  <a href="#Section_5.3"> (5.3)</a>
</li>
<li>
<span class="Italics">Serious <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span>: </span> Immediate medical
evaluation is recommended for serious <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> such as severe
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>.  <a href="#Section_5.4"> (5.4</a>, <a href="#Section_17.5"> 17.5)</a>
</li>
<li>
<span class="Italics">Nervous system symptoms (NSS):</span> NSS are frequent,
usually begin 1-2 days after initiating therapy and resolve in 2-4 weeks. Dosing at bedtime may improve tolerability. NSS are not predictive of onset
of <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span>. <a href="#Section_5.5"> (5.5</a>, <a href="#Section_6.1"> 6.1</a>, <a href="#Section_17.4">17.4)</a>
</li>
<li>
<span class="Italics">Pregnancy: </span> Fetal harm can occur when administered
to a pregnant woman during the first trimester. Women should be apprised of
the potential harm to the fetus.  <a href="#Section_5.6"> (5.6</a>, <a href="#Section_17.7"> 17.7)</a> Pregnancy registry is available.  <a href="#Section_8.1"> (8.1)</a>
</li>
<li>
<span class="Italics">Hepatotoxicity: </span> Monitor liver function tests before
and during treatment in patients with underlying <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C coinfection, marked transaminase elevations, or who are taking medications associated with liver toxicity. Among reported cases of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, a few occurred in patients with no pre-existing <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.  <a href="#Section_5.8"> (5.8</a>, <a href="#Section_6.1">6.1</a>,<a href="#Section_8.6"> 8.6)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>: </span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> usually begins within 1-2 weeks after
initiating therapy and resolves within 4 weeks. Discontinue if severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>
develops.  <a href="#Section_5.7"> (5.7</a>, <a href="#Section_6.1"> 6.1</a>, <a href="#Section_17.6"> 17.6)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>: </span> Use caution in patients with a history
of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.  <a href="#Section_5.9"> (5.9)</a>
</li>
<li>
<span class="Italics">Lipids: </span>Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglyceride elevations.
Monitor before therapy and periodically thereafter.  <a href="#Section_5.10"> (5.10)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span>: </span> May necessitate
further evaluation and treatment.  <a href="#Section_5.11"> (5.11)</a>
</li>
<li>
<span class="Italics">Redistribution/accumulation of body fat: </span> Observed
in patients receiving antiretroviral therapy.  <a href="#Section_5.12"> (5.12</a>, <a href="#Section_17.8"> 17.8)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most
common adverse reactions (&gt;5%, moderate-severe) are <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>,
<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.  <a href="#Section_6"> (6)</a> </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Coadministration of efavirenz can alter the concentrations of
other drugs and other drugs may alter the concentrations of efavirenz.  The
potential for drug-drug interactions must be considered before and during
therapy. <a href="#Section_4.2"> (4.2</a>, <a href="#Section_7.1"> 7.1</a>, <a href="#Section_12.3"> 12.3)</a> </p></div>
<div><div></div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics">Pregnancy:</span> Women should avoid pregnancy during
SUSTIVA therapy and for 12 weeks after discontinuation. <a href="#Section_5.6"> (5.6)</a>
</li>
<li>
<span class="Italics">Nursing mothers: </span> Women infected with HIV should
be instructed not to breast-feed. <a href="#Section_8.3"> (8.3)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>: </span>SUSTIVA is not recommended for patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Use caution in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. <a href="#Section_8.6"> (8.6)</a>
</li>
<li>
<span class="Italics">Pediatric patients: </span> The incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> was
higher than in adults. <a href="#Section_5.7"> (5.7</a>, <a href="#Section_6.1"> 6.1</a>, <a href="#Section_6.2"> 6.2</a>, <a href="#Section_8.4"> 8.4)</a>
</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 1/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1     INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2     DOSAGE AND ADMINISTRATION </a></h1>
<h2><a href="#section-2.1" class="toc">2.1     Adults</a></h2>
<h2><a href="#section-2.2" class="toc">2.2     Pediatric Patients</a></h2>
<h1><a href="#section-3" class="toc">3     DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4     CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1     <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-4.2" class="toc">4.2     Contraindicated Drugs</a></h2>
<h1><a href="#section-5" class="toc">5     WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1     Drug Interactions</a></h2>
<h2><a href="#section-5.2" class="toc">5.2     Resistance</a></h2>
<h2><a href="#section-5.3" class="toc">5.3     Coadministration with Related Products</a></h2>
<h2><a href="#section-5.4" class="toc">5.4     <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">Psychiatric Symptoms</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5     Nervous System Symptoms</a></h2>
<h2><a href="#section-5.6" class="toc">5.6     Reproductive Risk Potential</a></h2>
<h2><a href="#section-5.7" class="toc">5.7     <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8     Hepatotoxicity</a></h2>
<h2><a href="#section-5.9" class="toc">5.9     <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span></a></h2>
<h2><a href="#section-5.10" class="toc">5.10     Lipid Elevations</a></h2>
<h2><a href="#section-5.11" class="toc">5.11     <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></a></h2>
<h2><a href="#section-5.12" class="toc">5.12     Fat Redistribution</a></h2>
<h1><a href="#section-6" class="toc">6     ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1     Clinical Trials Experience in Adults</a></h2>
<h2><a href="#section-6.2" class="toc">6.2     Clinical Trial Experience in Pediatric Patients </a></h2>
<h2><a href="#section-6.3" class="toc">6.3     Postmarketing Experience </a></h2>
<h1><a href="#section-7" class="toc">7     DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1     Drug-Drug Interactions</a></h2>
<h2><a href="#section-7.2" class="toc">7.2     Cannabinoid Test Interaction</a></h2>
<h1><a href="#section-8" class="toc">8     USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1     Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3     Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4     Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5     Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6     <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10     OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11     DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12     CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1     Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3     Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4     Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13     NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1     Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2     Animal Toxicology</a></h2>
<h1><a href="#section-13" class="toc">14     CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16     HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1     Capsules</a></h2>
<h2><a href="#section-14.2" class="toc">16.2     Tablets</a></h2>
<h2><a href="#section-14.3" class="toc">16.3     Storage</a></h2>
<h1><a href="#section-15" class="toc">17     PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1     Drug Interactions</a></h2>
<h2><a href="#section-15.2" class="toc">17.2     General Information for Patients</a></h2>
<h2><a href="#section-15.3" class="toc">17.3     Dosing Instructions</a></h2>
<h2><a href="#section-15.4" class="toc">17.4     Nervous System Symptoms</a></h2>
<h2><a href="#section-15.5" class="toc">17.5     <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">Psychiatric Symptoms</span></a></h2>
<h2><a href="#section-15.6" class="toc">17.6     <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></a></h2>
<h2><a href="#section-15.7" class="toc">17.7     Reproductive Risk Potential</a></h2>
<h2><a href="#section-15.8" class="toc">17.8     Fat Redistribution</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1     INDICATIONS AND USAGE</h1>
<p class="First">SUSTIVA<span class="Sup">Â®</span> (efavirenz) in combination
with other antiretroviral agents is indicated for the treatment of human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span>
virus type 1 (HIV-1) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. This indication is based on two clinical trials
of at least one year duration that demonstrated prolonged suppression of HIV
RNA  [see <span class="Italics">Clinical Studies <a href="#Section_14"> (14)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2     DOSAGE AND ADMINISTRATION </h1>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1     Adults</h2>
<p class="First">The recommended dosage of SUSTIVA
(efavirenz) is 600 mg orally, once daily, in combination with a protease inhibitor
and/or nucleoside analogue reverse transcriptase inhibitors (NRTIs). It is
recommended that SUSTIVA be taken on an empty stomach, preferably at bedtime.
The increased efavirenz concentrations observed following administration of
SUSTIVA with food may lead to an increase in frequency of adverse reactions
[see <span class="Italics">Clinical Pharmacology <a href="#Section_12.3"> (12.3)</a></span>].
Dosing at bedtime may improve the tolerability of nervous system symptoms
 [see <span class="Italics">Warnings and Precautions <a href="#Section_5.5"> (5.5)</a>,
Adverse Reactions <a href="#Section_6.1"> (6.1)</a></span>, and <span class="Italics">Patient
Counseling Information <a href="#Section_17.4"> (17.4)</a></span>]. </p>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2.1.1"></a><a name="section-2.1.1"></a><p></p>
<h3 class="Bold">Concomitant Antiretroviral Therapy</h3>
<p class="First">SUSTIVA must be given in combination
with other antiretroviral medications  [see <span class="Italics">Indications and Usage <a href="#Section_1"> (1)</a>, Warnings and Precautions <a href="#Section_5.2"> (5.2)</a>,
Drug Interactions <a href="#Section_7.1"> (7.1)</a></span>, and <span class="Italics"> Clinical
Pharmacology <a href="#Section_12.3"> (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2.1.2"></a><a name="section-2.1.2"></a><p></p>
<h3 class="Bold">Dosage Adjustment</h3>
<p class="First">If SUSTIVA is coadministered with voriconazole, the voriconazole maintenance dose should be increased to 400
mg every 12 hours and the SUSTIVA dose should be decreased to 300 mg once daily using the capsule formulation (one 200-mg and two 50-mg capsules or
six 50-mg capsules).  SUSTIVA tablets should not be broken. See <span class="Italics">Drug Interactions <a href="#Section_7.1"> (7.1</a>, <a href="#table7"> Table 7)</a></span> and <span class="Italics">Clinical Pharmacology <a href="#Section_12.3"> (12.3</a>, <a href="#table8">Tables 8</a></span> and <span class="Italics"><a href="#table9"> 9)</a></span>.</p>
<p style="border-left:1px solid;"><span class="XmChange">If SUSTIVA is coadministered with rifampin to patients weighing 50 kg or more, an increase in the dose of SUSTIVA to 800 mg once daily is recommended [see <span class="Italics">Drug Interactions <a href="#Section_7.1"> (7.1</a>, <a href="#table7"> Table 7)</a></span> and <span class="Italics">Clinical Pharmacology <a href="#Section_12.3"> (12.3</a>,<a href="#table9"> Table 9)</a></span>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2     Pediatric Patients</h2>
<p class="First">It is recommended that SUSTIVA be
taken on an empty stomach, preferably at bedtime.  <a href="#table1"> Table 1</a> describes the recommended
dose of SUSTIVA for pediatric patients 3 years of age or older and weighing
between 10 and 40 kg [see <span class="Italics">Use in Specific Populations <a href="#Section_8.4"> (8.4)</a></span>]. The recommended dosage of SUSTIVA for pediatric patients weighing
greater than 40 kg is 600 mg once daily.</p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1:	Pediatric Dose to be Administered Once Daily</span></caption>
<col width="35%">
<col width="35%">
<col width="30%">
<thead>
<tr class="First">
<th class="Toprule" align="center" colspan="2" rowspan="1"><span class="Bold">Body Weight</span></th>
<th class="Toprule" align="center" colspan="1" rowspan="2"><span class="Bold">SUSTIVA Dose
(mg)</span></th>
</tr>
<tr class="Last">
<th class="Toprule" align="center" colspan="1" rowspan="1">kg</th>
<th class="Toprule" align="center" colspan="1" rowspan="1">lbs</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Toprule" align="center" colspan="1" rowspan="1">10 to less than
15</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">22 to less than
33</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">200</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">15 to less than 20</td>
<td align="center" colspan="1" rowspan="1">33 to less than 44</td>
<td align="center" colspan="1" rowspan="1">250</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">20 to less than 25</td>
<td align="center" colspan="1" rowspan="1">44 to less than 55</td>
<td align="center" colspan="1" rowspan="1">300</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">25 to less than 32.5</td>
<td align="center" colspan="1" rowspan="1">55 to less than 71.5</td>
<td align="center" colspan="1" rowspan="1">350</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">32.5 to less than 40</td>
<td align="center" colspan="1" rowspan="1">71.5 to less than 88</td>
<td align="center" colspan="1" rowspan="1">400</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center" colspan="1" rowspan="1">at least 40</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">at least 88</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">600</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3     DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">â€¢Â <span class="Italics">Capsules</span></p>
<p> Â Â Â Â Â 200-mg capsules are gold color, reverse printed with â€œSUSTIVAâ€? on the body and imprinted â€œ200Â mgâ€? on the cap.</p>
<p> Â Â Â Â Â 50-mg capsules are
gold color and white, printed with â€œSUSTIVAâ€? on the gold color cap and reverse
printed â€œ50Â mgâ€? on the white body.</p>
<p>â€¢Â <span class="Italics">Tablets</span></p>
<p> Â Â Â Â Â 600-mg tablets are yellow,
capsular-shaped, film-coated tablets, with â€œSUSTIVAâ€? printed on both sides.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4     CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4.1"></a><a name="section-4.1"></a><p></p>
<h2>4.1     <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">SUSTIVA is contraindicated in patients
with previously demonstrated clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>  (eg,
<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, or <span class="product-label-link" type="condition" conceptid="141370" conceptname="Toxic erythema">toxic skin eruptions</span>) to
any of the components of this product.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4.2"></a><a name="section-4.2"></a><p></p>
<h2>4.2     Contraindicated Drugs</h2>
<p class="First">For some drugs, competition for CYP3A
by efavirenz could result in inhibition of their metabolism and create the
potential for serious and/or life-threatening adverse reactions (eg, cardiac
<span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, prolonged sedation, or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>). Drugs that are
contraindicated with SUSTIVA are listed in <a href="#table2"> Table 2</a>.</p>
<a name="table2"></a><table width="100%">
<caption><span>Table 2:	Drugs That Are Contraindicated or Not Recommended for Use
With SUSTIVA</span></caption>
<col width="34%">
<col width="66%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" colspan="1" rowspan="1"><span class="Bold">Drug
Class: Drug Name</span></th>
<th class="Botrule Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">Clinical
Comment</span></th>
</tr></thead>
<tbody>
<tr class="First" valign="top">
<td align="left" colspan="1" rowspan="1">Antimigraine: ergot derivatives (dihydroergotamine,
ergonovine, ergotamine, methylergonovine)</td>
<td align="left" colspan="1" rowspan="1">Potential for serious and/or life-threatening
reactions such as acute ergot toxicity characterized by peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>
and <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities and other tissues.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Benzodiazepines: midazolam, triazolam</td>
<td align="left" colspan="1" rowspan="1">Potential for serious and/or life-threatening
reactions such as prolonged or increased sedation or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Calcium channel blocker:
bepridil</td>
<td align="left" colspan="1" rowspan="1">Potential for serious
and/or life-threatening reactions such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">GI motility agent: cisapride</td>
<td align="left" colspan="1" rowspan="1">Potential for serious and/or life-threatening
reactions such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Neuroleptic: pimozide</td>
<td align="left" colspan="1" rowspan="1">Potential for serious and/or life-threatening
reactions such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</td>
</tr>
<tr class="Last" valign="top">
<td class="Botrule" align="left" colspan="1" rowspan="1">St. Johnâ€™s wort <span class="Italics">(Hypericum
perforatum)</span>
</td>
<td class="Botrule" align="left" colspan="1" rowspan="1">May lead to loss
of virologic response and possible resistance to efavirenz or to the class
of non-nucleoside reverse transcriptase inhibitors (NNRTIs). </td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5     WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1     Drug Interactions</h2>
<p class="First">Efavirenz plasma concentrations may be altered by substrates, inhibitors, or inducers of CYP3A. Likewise, efavirenz
may alter plasma concentrations of drugs metabolized by CYP3A or CYP2B6 [see <span class="Italics">Contraindications <a href="#Section_4.2"> (4.2)</a></span> and <span class="Italics">Drug Interactions <a href="#Section_7.1"> (7.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2     Resistance</h2>
<p class="First">SUSTIVA must not be used as a single
agent to treat HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or added on as a sole agent to a failing regimen.
Resistant virus emerges rapidly when efavirenz is administered as monotherapy.
The choice of new antiretroviral agents to be used in combination with efavirenz
should take into consideration the potential for viral cross-resistance.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3     Coadministration with Related Products</h2>
<p class="First" style="border-left:1px solid;">Coadministration of SUSTIVA with ATRIPLA
(efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
is not recommended <span class="XmChange">unless needed for dose adjustment (eg, with rifampin)</span>, since efavirenz is one of its active ingredients.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4     <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">Psychiatric Symptoms</span></h2>
<p class="First">Serious psychiatric adverse experiences
have been reported in patients treated with SUSTIVA. In controlled trials
of 1008 patients treated with regimens containing SUSTIVA for a mean of 2.1
years and 635 patients treated with control regimens for a mean of 1.5 years,
the frequency (regardless of causality) of specific serious psychiatric events
among patients who received SUSTIVA or control regimens, respectively, were
severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (2.4%, 0.9%), <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> (0.7%, 0.3%), nonfatal <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>
attempts (0.5%, 0), <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> (0.4%, 0.5%), <span class="product-label-link" type="condition" conceptid="438737" conceptname="Acute paranoid reaction">paranoid reactions</span> (0.4%,
0.3%), and <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reactions</span> (0.2%, 0.3%). When <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> similar
to those noted above were combined and evaluated as a group in a multifactorial
analysis of data from Study 006, treatment with efavirenz was associated with
an increase in the occurrence of these selected <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span>. Other
factors associated with an increase in the occurrence of these psychiatric
symptoms were history of injection drug use, psychiatric history, and receipt
of psychiatric medication at study entry; similar associations were observed
in both the SUSTIVA and control treatment groups. In Study 006, onset of new
serious <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> occurred throughout the study for both SUSTIVA-treated
and control-treated patients. One percent of SUSTIVA-treated patients discontinued
or interrupted treatment because of one or more of these selected psychiatric
symptoms. There have also been occasional postmarketing reports of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> by
<span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusions</span>, and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>-like behavior, although a causal relationship
to the use of SUSTIVA cannot be determined from these reports. Patients with
serious psychiatric adverse experiences should seek immediate medical evaluation
to assess the possibility that the symptoms may be related to the use of SUSTIVA,
and if so, to determine whether the risks of continued therapy outweigh the
benefits. See <span class="Italics">Adverse Reactions <a href="#Section_6.1"> (6.1)</a></span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5     Nervous System Symptoms</h2>
<p class="First">Fifty-three percent (531/1008) of
patients receiving SUSTIVA in controlled trials reported central nervous system
symptoms (any grade, regardless of causality) compared to 25% (156/635) of
patients receiving control regimens [see <span class="Italics">Adverse Reactions <a href="#Section_6.1"> (6.1</a>, <a href="#table4"> Table 4)</a></span>]. These symptoms included, but
were not limited to, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (28.1% of the 1008 patients), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (16.3%),
impaired concentration (8.3%), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (7.0%), <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span> (6.2%),
and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> (1.2%). These symptoms were severe in 2.0% of patients,
and 2.1% of patients discontinued therapy as a result. These symptoms usually
begin during the first or second day of therapy and generally resolve after
the first 2-4 weeks of therapy. After 4 weeks of therapy, the prevalence of
nervous system symptoms of at least moderate severity ranged from 5% to 9%
in patients treated with regimens containing SUSTIVA and from 3% to 5% in
patients treated with a control regimen. Patients should be informed that
these common symptoms were likely to improve with continued therapy and were
not predictive of subsequent onset of the less frequent <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span>
[see <span class="Italics">Warnings and Precautions <a href="#Section_5.4"> (5.4)</a></span>].
Dosing at bedtime may improve the tolerability of these nervous system symptoms
[see <span class="Italics">Dosage and Administration <a href="#Section_2"> (2)</a></span>].</p>
<p>Analysis of long-term data from Study 006 (median follow-up 180
weeks, 102 weeks, and 76 weeks for patients treated with SUSTIVA + zidovudine
+ lamivudine, SUSTIVA + indinavir, and indinavir + zidovudine + lamivudine,
respectively) showed that, beyond 24 weeks of therapy, the incidences of new-onset
nervous system symptoms among SUSTIVA-treated patients were generally similar
to those in the indinavir-containing control arm.</p>
<p>Patients
receiving SUSTIVA should be alerted to the potential for additive central
nervous system effects when SUSTIVA is used concomitantly with alcohol or
psychoactive drugs.</p>
<p>Patients who experience central
nervous system symptoms such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, impaired concentration, and/or
<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> should avoid potentially hazardous tasks such as driving or operating
machinery.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6     Reproductive Risk Potential</h2>
<p class="First"><span class="Bold">Pregnancy Category D. </span>
									Efavirenz may cause fetal harm when administered during the first trimester to a pregnant
woman. Pregnancy should be avoided in women receiving SUSTIVA. Barrier contraception must always be used in combination with other methods of contraception (eg, oral or other hormonal contraceptives). Because of the long half-life of efavirenz, use of adequate contraceptive measures for 12 weeks after discontinuation of SUSTIVA is recommended. Women of childbearing potential should undergo pregnancy testing before initiation of SUSTIVA. If this drug is used during the first trimester of pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to
the fetus.</p>
<p>There are no adequate and well-controlled studies in pregnant women. SUSTIVA should be used during
pregnancy only if the potential benefit justifies the potential risk to the fetus, such as in pregnant women without other therapeutic options. [See <span class="Italics">Use in Specific Populations <a href="#Section_8.1"> (8.1)</a></span>.]
								</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7     <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></h2>
<p class="First" style="border-left:1px solid;">In controlled clinical trials, 26% (266/1008) of patients treated with 600 mg SUSTIVA experienced new-onset skin
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> compared with 17% (111/635) of patients treated in control groups [see <span class="Italics">Adverse Reactions <a href="#Section_6.1"> (6.1</a>, <a href="#table5"> Table 5)</a></span>]. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> associated with <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, moist <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>, or ulceration occurred
in 0.9% (9/1008) of patients treated with SUSTIVA. The incidence of Grade 4 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (eg, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>) in patients treated
with SUSTIVA in all studies and expanded access was 0.1%. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rashes</span> are usually mild-to-moderate maculopapular <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span> that occur within the first
2 weeks of initiating therapy with efavirenz (median time to onset of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in adults was 11 days) and, in most patients continuing therapy with efavirenz,
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> resolves within 1 month (median duration, 16 days). The discontinuation rate for <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in clinical trials was 1.7% (17/1008). SUSTIVA can be reinitiated
in patients interrupting therapy because of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. SUSTIVA should be discontinued in patients developing severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> associated with <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blistering</span>, <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>,
mucosal involvement, or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. Appropriate antihistamines and/or corticosteroids may improve the tolerability and hasten the resolution of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. <span class="XmChange">For patients who have had a life-threatening cutaneous reaction (eg, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>), alternative therapy should be considered [see also <span class="Italics">Contraindications <a href="#Section_4.1"> (4.1)</a></span>].</span></p>
<p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> was reported in 26 of 57 pediatric patients (46%) treated with SUSTIVA capsules [see <span class="Italics">Adverse Reactions <a href="#Section_6.1"> (6.1</a>, <a href="#Section_6.2"> 6.2)</a></span>]. One pediatric patient experienced Grade 3 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (confluent <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>), and two patients had Grade 4 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (<span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>). The median time to onset of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in pediatric patients was 8 days. Prophylaxis with appropriate antihistamines before initiating therapy with SUSTIVA in pediatric patients should be considered.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8     Hepatotoxicity</h2>
<p class="First">Monitoring of liver enzymes before and during treatment is recommended for patients with underlying <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; patients with marked transaminase elevations; and patients treated with other medications associated with liver toxicity [see <span class="Italics">Adverse Reactions <a href="#Section_6.1"> (6.1)</a></span> and <span class="Italics">Use in Specific Populations <a href="#Section_8.6"> (8.6)</a></span>]. A few of the postmarketing reports of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> occurred in patients with no pre-existing <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> or other identifiable risk factors [see <span class="Italics">Adverse Reactions <a href="#Section_6.3"> (6.3)</a></span>]. Liver enzyme monitoring should also be considered for patients without pre-existing hepatic dysfunction or other risk factors. In patients with persistent elevations of serum transaminases to greater than five times the upper limit of the normal range, the benefit of continued therapy with SUSTIVA needs to be weighed against the unknown risks of significant liver toxicity. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9     <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> have been observed in
patients receiving efavirenz, generally in the presence of known medical history
of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> [see <span class="Italics">Nonclinical Toxicology <a href="#Section_13.2"> (13.2)</a></span>].
Caution must be taken in any patient with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Patients
who are receiving concomitant anticonvulsant medications primarily metabolized
by the liver, such as phenytoin and phenobarbital, may require periodic monitoring
of plasma levels [see <span class="Italics">Drug Interactions <a href="#Section_7.1"> (7.1)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10     Lipid Elevations</h2>
<p class="First">Treatment with SUSTIVA has resulted
in increases in the concentration of total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglycerides [see <span class="Italics">Adverse
Reactions <a href="#Section_6.1"> (6.1)</a></span>]. <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> and
triglyceride testing should be performed before initiating SUSTIVA therapy
and at periodic intervals during therapy.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11     <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has
been reported in patients treated with combination antiretroviral therapy,
including SUSTIVA. During the initial phase of combination antiretroviral
treatment, patients whose immune system responds may develop an inflammatory
response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> [such as <span class="Italics">Mycobacterium
avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jiroveci </span> 
<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (PCP), or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>], which may necessitate further evaluation
and treatment.</p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="434621" conceptname="Autoimmune disease">Autoimmune disorders</span> (such as Gravesâ€™ disease, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and Guillain-BarrÃ© syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12     Fat Redistribution</h2>
<p class="First">Redistribution/accumulation of body
fat including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>),
peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and â€œcushingoid appearanceâ€?
have been observed in patients receiving antiretroviral therapy. The mechanism
and long-term consequences of these events are currently unknown. A causal
relationship has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6     ADVERSE REACTIONS</h1>
<p class="First">The most significant adverse reactions
observed in patients treated with SUSTIVA are:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span>  [see <span class="Italics">Warnings and Precautions <a href="#Section_5.4"> (5.4)</a></span>],</li>
<li>nervous system symptoms  [see <span class="Italics">Warnings and Precautions <a href="#Section_5.5"> (5.5)</a></span>],</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> [see <span class="Italics">Warnings and Precautions <a href="#Section_5.7"> (5.7)</a></span>].</li>
</ul>
<p>The most common (&gt;5% in either efavirenz treatment group)
adverse reactions of at least moderate severity among patients in Study 006
treated with SUSTIVA in combination with zidovudine/lamivudine or indinavir
were <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1     Clinical Trials Experience in Adults</h2>
<p class="First">Because clinical studies are conducted
under widely varying conditions, the adverse reaction rates reported cannot
be directly compared to rates in other clinical studies and may not reflect
the rates observed in clinical practice.</p>
<p>Selected
clinical adverse reactions of moderate or severe intensity observed in â‰¥2%
of SUSTIVA-treated patients in two controlled clinical trials are presented
in <a href="#table3"> Table 3</a>.</p>
<a name="table3"></a><table width="100%">
<caption><span>Table 3:	Selected Treatment-Emergent<span class="Sup">a</span> Adverse
Reactions of Moderate or Severe Intensity Reported in â‰¥2% of SUSTIVA-Treated
Patients in Studies 006 and ACTGÂ 364</span></caption>
<colgroup>
<col width="25%">
<col width="13%">
<col width="12%">
<col width="13%">
<col width="12%">
<col width="13%">
<col width="12%">
</colgroup>
<thead>
<tr class="First">
<td class="Toprule" align="center"></td>
<td class="Botrule Toprule" align="center" colspan="3"><span class="Bold">Study 006<br> LAM-,
NNRTI-, and Protease Inhibitor-Naive Patients</span></td>
<td class="Botrule Toprule" align="center" colspan="3"><span class="Bold">Study ACTG 364<br> NRTI-experienced,
NNRTI-, and Protease Inhibitor-Naive Patients</span></td>
</tr>
<tr>
<th align="left" rowspan="2" valign="bottom">Adverse Reactions</th>
<td align="center" valign="bottom">SUSTIVA<span class="Sup">b</span><br>+<br>ZDV/LAM<br>(n=412)</td>
<td align="center" valign="bottom">SUSTIVA<span class="Sup">b</span><br>+<br>Indinavir<br>(n=415)</td>
<td align="center" valign="bottom">Indinavir<br>+<br>ZDV/LAM<br>(n=401)</td>
<td align="center" valign="bottom">SUSTIVA<span class="Sup">b</span><br>+ Nelfinavir<br>+ NRTIs <br>(n=64)</td>
<td align="center" valign="bottom">SUSTIVA<span class="Sup">b</span><br>+<br> NRTIs<br>(n=65)</td>
<td align="center" valign="bottom">Nelfinavir<br>+<br>NRTIs<br>(n=66)</td>
</tr>
<tr class="Last">
<td align="center" valign="bottom">180 weeks<span class="Sup">c</span>
</td>
<td align="center" valign="bottom">102 weeks<span class="Sup">c</span>
</td>
<td align="center" valign="bottom">76 weeks<span class="Sup">c</span>
</td>
<td align="center" valign="bottom">71.1 weeks<span class="Sup">c</span>
</td>
<td align="center" valign="bottom">70.9 weeks<span class="Sup">c</span>
</td>
<td align="center" valign="bottom">62.7 weeks<span class="Sup">c</span>
</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td colspan="7">
<span class="Sup">a</span> Includes adverse events at least
possibly related to study drug or of unknown relationship for Study 006. Includes
all adverse events regardless of relationship to study drug for Study ACTG
364.</td></tr>
<tr><td colspan="7">
<span class="Sup">b</span> SUSTIVA provided as 600 mg once
daily.</td></tr>
<tr><td colspan="7">
<span class="Sup">c</span> Median duration of treatment.</td></tr>
<tr><td colspan="7">
<span class="Sup">d</span> Includes <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>,
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> follicular, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculopapular, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">rash petechial</span>,
<span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">rash pustular</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> for Study 006 and <span class="product-label-link" type="condition" conceptid="4010895" conceptname="Macule">macules</span>, <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>,
<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">allergic rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">welts</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span>, and
<span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> for ACTG 364.</td></tr>
<tr><td colspan="7">â€” = Not Specified.</td></tr>
<tr class="Last"><td colspan="7">ZDV = zidovudine, LAM = lamivudine.</td></tr>
</tfoot>
<tbody>
<tr class="First"><td class="Toprule" colspan="7"><span class="Bold">Body as a Whole</span></td></tr>
<tr>
<td>Â Â  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">8%</td>
<td align="center">5%</td>
<td align="center">9%</td>
<td align="center">0</td>
<td align="center">2%</td>
<td align="center">3%</td>
</tr>
<tr>
<td>Â Â  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td align="center">1%</td>
<td align="center">2%</td>
<td align="center">8%</td>
<td align="center">13%</td>
<td align="center">6%</td>
<td align="center">17%</td>
</tr>
<tr><td colspan="7"><span class="Bold">Central and Peripheral Nervous System</span></td></tr>
<tr>
<td> Â Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">9%</td>
<td align="center">9%</td>
<td align="center">2%</td>
<td align="center">2%</td>
<td align="center">6%</td>
<td align="center">6%</td>
</tr>
<tr>
<td> Â Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center">8%</td>
<td align="center">5%</td>
<td align="center">3%</td>
<td align="center">5%</td>
<td align="center">2%</td>
<td align="center">3%</td>
</tr>
<tr>
<td> Â Â <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center">7%</td>
<td align="center">7%</td>
<td align="center">2%</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2%</td>
</tr>
<tr>
<td> Â Â <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">Concentration impaired</span></td>
<td align="center">5%</td>
<td align="center">3%</td>
<td align="center">&lt;1%</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td> Â Â <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span></td>
<td align="center">3%</td>
<td align="center">1%</td>
<td align="center">0</td>
<td align="center">â€”</td>
<td align="center">â€”</td>
<td align="center">â€”</td>
</tr>
<tr>
<td> Â Â <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">2%</td>
<td align="center">2%</td>
<td align="center">&lt;1%</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td> Â Â <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center">1%</td>
<td align="center">&lt;1%</td>
<td align="center">&lt;1%</td>
<td align="center">0</td>
<td align="center">2%</td>
<td align="center">2%</td>
</tr>
<tr><td colspan="7"><span class="Bold">Gastrointestinal</span></td></tr>
<tr>
<td>Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">10%</td>
<td align="center">6%</td>
<td align="center">24%</td>
<td align="center">3%</td>
<td align="center">2%</td>
<td align="center">2%</td>
</tr>
<tr>
<td>Â Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">6%</td>
<td align="center">3%</td>
<td align="center">14%</td>
<td align="center">â€”</td>
<td align="center">â€”</td>
<td align="center">â€”</td>
</tr>
<tr>
<td>Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">3%</td>
<td align="center">5%</td>
<td align="center">6%</td>
<td align="center">14%</td>
<td align="center">3%</td>
<td align="center">9%</td>
</tr>
<tr>
<td>Â Â <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center">4%</td>
<td align="center">4%</td>
<td align="center">6%</td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">2%</td>
</tr>
<tr>
<td>Â Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td align="center">2%</td>
<td align="center">2%</td>
<td align="center">5%</td>
<td align="center">3%</td>
<td align="center">3%</td>
<td align="center">3%</td>
</tr>
<tr><td colspan="7"><span class="Bold">Psychiatric</span></td></tr>
<tr>
<td>Â Â <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td align="center">2%</td>
<td align="center">4%</td>
<td align="center">&lt;1%</td>
<td align="center">â€”</td>
<td align="center">â€”</td>
<td align="center">â€”</td>
</tr>
<tr>
<td>Â Â <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="center">5%</td>
<td align="center">4%</td>
<td align="center">&lt;1%</td>
<td align="center">3%</td>
<td align="center">0</td>
<td align="center">5%</td>
</tr>
<tr>
<td>Â Â <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td align="center">2%</td>
<td align="center">2%</td>
<td align="center">0</td>
<td align="center">2%</td>
<td align="center">0</td>
<td align="center">2%</td>
</tr>
<tr><td colspan="7"><span class="Bold">Skin &amp; Appendages</span></td></tr>
<tr>
<td>Â Â <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><span class="Sup">d</span>
</td>
<td align="center">11%</td>
<td align="center">16%</td>
<td align="center">5%</td>
<td align="center">9%</td>
<td align="center">5%</td>
<td align="center">9%</td>
</tr>
<tr class="Last">
<td class="Botrule">Â Â <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Botrule" align="center">&lt;1%</td>
<td class="Botrule" align="center">1%</td>
<td class="Botrule" align="center">1%</td>
<td class="Botrule" align="center">9%</td>
<td class="Botrule" align="center">5%</td>
<td class="Botrule" align="center">9%</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span> has been reported, although a causal
relationship with efavirenz has not been established. Asymptomatic increases
in serum amylase levels were observed in a significantly higher number of
patients treated with efavirenz 600 mg than in control patients (see <span class="Italics"><a href="#Section_6.1.6"> Laboratory Abnormalities</a></span>).</p>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6.1.3"></a><a name="section-6.1.1"></a><p></p>
<h3 class="Bold">Nervous System Symptoms </h3>
<p class="First">For 1008 patients treated with regimens
containing SUSTIVA and 635 patients treated with a control regimen in controlled
trials, <a href="#table4"> Table 4</a> lists the frequency of symptoms of different degrees of severity
and gives the discontinuation rates for one or more of the following nervous
system symptoms: <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, impaired concentration, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>,
abnormal dreaming, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>,
<span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span>, and <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span> [see <span class="Italics">Warnings and
Precautions <a href="#Section_5.5"> (5.5)</a></span>]. The frequencies
of specific central and peripheral nervous system symptoms are provided in <a href="#table3"> Table 3</a>.</p>
<a name="table4"></a><table width="100%">
<caption><span>Table 4:	Percent of Patients with One or More Selected Nervous System
Symptoms<span class="Sup">a,b</span></span></caption>
<col width="34%">
<col width="33%">
<col width="33%">
<thead>
<tr class="First">
<th class="Toprule" align="left" rowspan="2"><span class="Bold">Percent of Patients
with:</span></th>
<th class="Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">SUSTIVA
600 mg Once Daily<br>(n=1008)</span></th>
<th class="Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">Control
Groups<br>(n=635)</span></th>
</tr>
<tr class="Last">
<th align="center" colspan="1" rowspan="1"><span class="Bold">%</span></th>
<th align="center"><span class="Bold">%</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td colspan="3" rowspan="1">
<span class="Sup">a</span>Â Â Includes events
reported regardless of causality.</td></tr>
<tr><td colspan="3" rowspan="1">
<span class="Sup">b</span>Â Â Data from Study
006 and three Phase 2/3 studies.</td></tr>
<tr><td colspan="3" rowspan="1">
<span class="Sup">c</span>Â Â â€œMildâ€? = Symptoms
which do not interfere with patientâ€™s daily activities.</td></tr>
<tr><td colspan="3" rowspan="1">
<span class="Sup">d</span>Â Â â€œModerateâ€? = Symptoms
which may interfere with daily activities.</td></tr>
<tr class="Last"><td colspan="3" rowspan="1">
<span class="Sup">e</span>Â Â â€œSevereâ€? = Events
which interrupt patientâ€™s usual daily activities.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Toprule" colspan="1" rowspan="1">Symptoms of any severity</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">52.7</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">24.6</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Mild symptoms<span class="Sup">c</span>
</td>
<td align="center" colspan="1" rowspan="1">33.3</td>
<td align="center" colspan="1" rowspan="1">15.6</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Moderate symptoms<span class="Sup">d</span>
</td>
<td align="center" colspan="1" rowspan="1">17.4</td>
<td align="center" colspan="1" rowspan="1">7.7</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Severe symptoms<span class="Sup">e</span>
</td>
<td align="center" colspan="1" rowspan="1">2.0</td>
<td align="center" colspan="1" rowspan="1">1.3</td>
</tr>
<tr class="Last">
<td class="Botrule" colspan="1" rowspan="1">Treatment discontinuation as
a result of symptoms</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">2.1</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">1.1</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6.1.4"></a><a name="section-6.1.2"></a><p></p>
<h3 class="Bold"><span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">Psychiatric Symptoms</span></h3>
<p class="First">Serious psychiatric adverse experiences
have been reported in patients treated with SUSTIVA.  In controlled trials,
<span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> observed at a frequency of &gt;2% among patients treated
with SUSTIVA or control regimens, respectively, were <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (19%, 16%),
<span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> (13%, 9%), and <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> (7%, 2%).</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6.1.5"></a><a name="section-6.1.3"></a><p></p>
<h3 class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></h3>
<p class="First">For 1008 adult and 57 pediatric
patients treated with regimens containing SUSTIVA and 635 patients treated
with a control regimen in controlled trials, the frequency of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> by NCI
grade and the discontinuation rates as a result of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in clinical studies
are provided in <a href="#table5"> Table 5</a> [see <span class="Italics">Warnings and Precautions <a href="#Section_5.7">(5.7)</a></span>].</p>
<a name="table5"></a><table width="100%">
<caption><span>Table 5:	Percent of Patients with Treatment-Emergent <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span><span class="Sup">a,b</span></span></caption>
<col width="18%">
<col width="35%">
<col width="17%">
<col width="15%">
<col width="15%">
<thead>
<tr class="First">
<th class="Toprule" align="left" rowspan="2"><span class="Bold">Percent of Patients with:</span></th>
<th class="Toprule" align="center" rowspan="2"><span class="Bold">Description of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> Grade<span class="Sup">c</span></span></th>
<th class="Toprule" align="center" colspan="1" rowspan="1" valign="bottom"><span class="Bold">SUSTIVA
600 mg Once Daily Adults<br>(n=1008)</span></th>
<th class="Toprule" align="center" colspan="1" rowspan="1" valign="bottom"><span class="Bold">SUSTIVA<br>Pediatric
Patients<br>(n=57)</span></th>
<th class="Toprule" align="center" colspan="1" rowspan="1" valign="bottom"><span class="Bold">Control
Groups<br>Adults<br>(n=635)</span></th>
</tr>
<tr class="Last">
<th align="center" colspan="1" rowspan="1"><span class="Bold">%</span></th>
<th align="center" colspan="1" rowspan="1"><span class="Bold">%</span></th>
<th align="center" colspan="1" rowspan="1"><span class="Bold">%</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td colspan="5" rowspan="1">
<span class="Sup">a</span>Â Â Includes events
reported regardless of causality.</td></tr>
<tr><td colspan="5" rowspan="1">
<span class="Sup">b</span>Â Â Data from Study
006 and three Phase 2/3 studies.</td></tr>
<tr class="Last"><td colspan="5" rowspan="1">
<span class="Sup">c</span>Â Â NCI Grading System.</td></tr>
</tfoot>
<tbody>
<tr class="First" valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> of any grade</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â€”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">26.3</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">45.6</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">17.5</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Grade 1 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></td>
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
<td align="center" colspan="1" rowspan="1">10.7</td>
<td align="center" colspan="1" rowspan="1">8.8</td>
<td align="center" colspan="1" rowspan="1">9.8</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Grade 2 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></td>
<td align="left" colspan="1" rowspan="1">Diffuse <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, dry <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span></td>
<td align="center" colspan="1" rowspan="1">14.7</td>
<td align="center" colspan="1" rowspan="1">31.6</td>
<td align="center" colspan="1" rowspan="1">7.4</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Grade 3 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></td>
<td align="left" colspan="1" rowspan="1">Vesiculation, moist <span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span>,
ulceration</td>
<td align="center" colspan="1" rowspan="1">0.8</td>
<td align="center" colspan="1" rowspan="1">1.8</td>
<td align="center" colspan="1" rowspan="1">0.3</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Grade 4 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></td>
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span>, Stevens-Johnson
syndrome, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> requiring surgery, exfoliative
<span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span></td>
<td align="center" colspan="1" rowspan="1">0.1</td>
<td align="center" colspan="1" rowspan="1">3.5</td>
<td align="center" colspan="1" rowspan="1">0.0</td>
</tr>
<tr class="Last" valign="top">
<td class="Botrule" align="left" colspan="1" rowspan="1">Treatment discontinuation
as a result of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></td>
<td class="Botrule" align="center" colspan="1" rowspan="1">â€”</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">1.7</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">8.8</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">0.3</td>
</tr>
</tbody>
</table>
<p>As seen in <a href="#table5"> Table 5</a>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> is more common in pediatric
patients and more often of higher grade (ie, more severe) [see <span class="Italics">Warnings
and Precautions <a href="#Section_5.7"> (5.7)</a></span>].</p>
<p>Experience with SUSTIVA in patients who discontinued other antiretroviral
agents of the NNRTI class is limited. Nineteen patients who discontinued nevirapine
because of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> have been treated with SUSTIVA. Nine of these patients developed
mild-to-moderate <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> while receiving therapy with SUSTIVA, and two of these
patients discontinued because of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6.1.6"></a><a name="section-6.1.4"></a><p></p>
<h3 class="Bold">Laboratory Abnormalities</h3>
<p class="First">Selected Grade 3-4 laboratory abnormalities
reported in â‰¥2% of SUSTIVA-treated patients in two clinical trials are presented
in <a href="#table6"> Table 6</a>.</p>
<a name="table6"></a><table width="100%">
<caption><span>Table 6:	Selected Grade 3-4 Laboratory Abnormalities Reported in â‰¥2% of SUSTIVA-Treated Patients in Studies 006 and ACTG 364</span></caption>
<col width="14%">
<col width="10%">
<col width="14%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="12%">
<col width="14%">
<thead>
<tr class="First" valign="bottom">
<th class="Toprule" align="center" colspan="2">Â </th>
<th class="Botrule Toprule" align="center" colspan="3"><span class="Bold">Study 006<br> LAM-,
NNRTI-, and Protease<br>Inhibitor-Naive Patients</span></th>
<th class="Botrule Toprule" align="center" colspan="3"><span class="Bold">Study ACTG 364<br> NRTI-experienced,<br>
NNRTI-, and Protease<br>Inhibitor-Naive Patients</span></th>
</tr>
<tr>
<td align="center" rowspan="2" valign="bottom">Variable</td>
<td align="center" rowspan="2" valign="bottom">Limit</td>
<td align="center" colspan="1" rowspan="1" valign="bottom">SUSTIVA<span class="Sup">a</span><br>+ ZDV/LAM<br>(n=412)</td>
<td align="center" colspan="1" rowspan="1" valign="bottom">SUSTIVA<span class="Sup">a</span><br>+ Indinavir<br>(n=415)</td>
<td align="center" colspan="1" rowspan="1" valign="bottom">Indinavir<br>+ ZDV/LAM<br>(n=401)</td>
<td align="center" colspan="1" rowspan="1" valign="bottom">SUSTIVA<span class="Sup">a</span><br>+ Nelfinavir<br>+ NRTIs<br>(n=64)</td>
<td align="center" colspan="1" rowspan="1" valign="bottom">SUSTIVA<span class="Sup">a</span><br>+ NRTIs<br>(n=65)</td>
<td align="center" colspan="1" rowspan="1" valign="bottom">Nelfinavir<br>+ NRTIs<br>(n=66)</td>
</tr>
<tr class="Last" valign="bottom">
<td align="center" colspan="1" rowspan="1">180 weeks<span class="Sup">b</span>
</td>
<td align="center" colspan="1" rowspan="1">102 weeks<span class="Sup">b</span>
</td>
<td align="center" colspan="1" rowspan="1">76 weeks<span class="Sup">b</span>
</td>
<td align="center" colspan="1" rowspan="1">71.1 weeks<span class="Sup">b</span>
</td>
<td align="center" colspan="1" rowspan="1">70.9 weeks<span class="Sup">b</span>
</td>
<td align="center" colspan="1" rowspan="1">62.7 weeks<span class="Sup">b</span>
</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td colspan="8" rowspan="1">
<span class="Sup">a</span>Â Â SUSTIVA provided
as 600 mg once daily.</td></tr>
<tr><td colspan="8" rowspan="1">
<span class="Sup">b</span>Â Â Median duration
of treatment.</td></tr>
<tr><td colspan="8" rowspan="1">
<span class="Sup">c</span>Â Â Isolated elevations
of GGT in patients receiving SUSTIVA may reflect enzyme induction not associated
with liver toxicity.</td></tr>
<tr><td colspan="8" rowspan="1">
<span class="Sup">d</span>Â Â Nonfasting.</td></tr>
<tr class="Last"><td align="left" colspan="8" rowspan="1">ZDV = zidovudine, LAM = lamivudine,
ULN = Upper limit of normal, ALT = <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span>,<br>AST = <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span>, GGT = gamma-glutamyltransferase.</td></tr>
</tfoot>
<tbody>
<tr class="First"><td class="Toprule" align="left" colspan="8" rowspan="1">Chemistry</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â ALT</td>
<td align="center" colspan="1" rowspan="1">&gt;5 x ULN</td>
<td align="center" colspan="1" rowspan="1">5%</td>
<td align="center" colspan="1" rowspan="1">8%</td>
<td align="center" colspan="1" rowspan="1">5%</td>
<td align="center" colspan="1" rowspan="1">2%</td>
<td align="center" colspan="1" rowspan="1">6%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â AST</td>
<td align="center" colspan="1" rowspan="1">&gt;5 x ULN</td>
<td align="center" colspan="1" rowspan="1">5%</td>
<td align="center" colspan="1" rowspan="1">6%</td>
<td align="center" colspan="1" rowspan="1">5%</td>
<td align="center" colspan="1" rowspan="1">6%</td>
<td align="center" colspan="1" rowspan="1">8%</td>
<td align="center" colspan="1" rowspan="1">8%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â GGT<span class="Sup">c</span>
</td>
<td align="center" colspan="1" rowspan="1">&gt;5 x ULN</td>
<td align="center" colspan="1" rowspan="1">8%</td>
<td align="center" colspan="1" rowspan="1">7%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
<td align="center" colspan="1" rowspan="1">5%</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">5%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Amylase</td>
<td align="center" colspan="1" rowspan="1">&gt;2 x ULN</td>
<td align="center" colspan="1" rowspan="1">4%</td>
<td align="center" colspan="1" rowspan="1">4%</td>
<td align="center" colspan="1" rowspan="1">1%</td>
<td align="center" colspan="1" rowspan="1">0</td>
<td align="center" colspan="1" rowspan="1">6%</td>
<td align="center" colspan="1" rowspan="1">2%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Glucose</td>
<td align="center" colspan="1" rowspan="1">&gt;250 mg/dL</td>
<td align="center" colspan="1" rowspan="1">3%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
<td align="center" colspan="1" rowspan="1">5%</td>
<td align="center" colspan="1" rowspan="1">2%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Triglycerides<span class="Sup">d</span>
</td>
<td align="center" colspan="1" rowspan="1">â‰¥751 mg/dL</td>
<td align="center" colspan="1" rowspan="1">9%</td>
<td align="center" colspan="1" rowspan="1">6%</td>
<td align="center" colspan="1" rowspan="1">6%</td>
<td align="center" colspan="1" rowspan="1">11%</td>
<td align="center" colspan="1" rowspan="1">8%</td>
<td align="center" colspan="1" rowspan="1">17%</td>
</tr>
<tr><td align="left" colspan="8" rowspan="1">Hematology</td></tr>
<tr class="Last">
<td class="Botrule" align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span></td>
<td align="center" colspan="1" rowspan="1">&lt;750/mm<span class="Sup">3</span>
</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">10%</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">3%</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">5%</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">2%</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">3%</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">2%</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6.1.6.1"></a><a name="section-6.1.4.1"></a><p></p>
<h4 class="Bold">Patients Coinfected with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B or C</h4>
<p class="First">Liver function tests should be monitored in patients with a history of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or C. In the long-term data set from Study 006, 137 patients treated with SUSTIVA-containing regimens (median duration
of therapy, 68 weeks) and 84 treated with a control regimen (median duration,
56 weeks) were seropositive at screening for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B (surface antigen
positive) and/or C (<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C antibody positive). Among these coinfected
patients, elevations in AST to greater than five times ULN developed in 13%
of patients in the SUSTIVA arms and 7% of those in the control arm, and elevations
in ALT to greater than five times ULN developed in 20% of patients in the
SUSTIVA arms and 7% of patients in the control arm. Among coinfected patients,
3% of those treated with SUSTIVA-containing regimens and 2% in the control
arm discontinued from the study because of liver or biliary system disorders
[see <span class="Italics">Warnings and Precautions <a href="#Section_5.8"> (5.8)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6.1.6.2"></a><a name="section-6.1.4.2"></a><p></p>
<h4 class="Bold">Lipids</h4>
<p class="First">Increases from baseline in total
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> of 10-20% have been observed in some uninfected volunteers receiving
SUSTIVA. In patients treated with SUSTIVA + zidovudine + lamivudine, increases
from baseline in nonfasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and HDL of approximately 20%
and 25%, respectively, were observed. In patients treated with SUSTIVA + indinavir,
increases from baseline in nonfasting <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and HDL of approximately
40% and 35%, respectively, were observed. Nonfasting total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> levels â‰¥240 mg/dL and â‰¥300 mg/dL were reported in 34% and 9%, respectively, of patients
treated with SUSTIVA + zidovudine + lamivudine; 54% and 20%, respectively,
of patients treated with SUSTIVA + indinavir; and 28% and 4%, respectively,
of patients treated with indinavir + zidovudine + lamivudine. The effects
of SUSTIVA on triglycerides and LDL in this study were not well characterized
since samples were taken from nonfasting patients. The clinical significance
of these findings is unknown  [see <span class="Italics">Warnings and Precautions <a href="#Section_5.10"> (5.10)</a></span>].</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2     Clinical Trial Experience in Pediatric Patients </h2>
<p class="First">Clinical adverse experiences observed
in â‰¥10% of 57 pediatric patients aged 3 to 16 years who received SUSTIVA capsules,
nelfinavir, and one or more NRTIs in Study ACTG 382 [see <span class="Italics">Use In Specific
Populations <a href="#Section_8.4"> (8.4)</a></span>] were <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (46%),
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (39%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (21%), <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> (16%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/lightheaded/<span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>
(16%), <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">ache</span>/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>/<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> (14%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (12%), and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (11%).
The incidence of nervous system symptoms was 18% (10/57). One patient experienced
Grade 3 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, two patients had Grade 4 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and five patients (9%) discontinued
because of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> [see <span class="Italics">Warnings and Precautions <a href="#Section_5.7"> (5.7)</a></span> and <span class="Italics">Adverse
Reactions <a href="#Section_6.1"> (6.1</a>, <a href="#table5">Table 5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3     Postmarketing Experience </h2>
<p class="First">The following adverse reactions have
been identified during postapproval use of SUSTIVA. Because these reactions
are reported voluntarily from a population of unknown size, it is not always
possible to reliably estimate their frequency or establish a causal relationship
to drug exposure. </p>
<p><span class="Italics">Body as a Whole: </span>allergic
reactions, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, redistribution/accumulation of body fat [see <span class="Italics"> Warnings
and Precautions <a href="#Section_5.12"> (5.12)</a></span>]</p>
<p><span class="Italics">Central and Peripheral Nervous System: </span>abnormal
coordination, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, cerebellar coordination and balance disturbances, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>,
<span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Italics">Endocrine: </span> <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span></p>
<p><span class="Italics">Gastrointestinal: </span> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption</span> </p>
<p><span class="Italics">Cardiovascular: </span> <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span></p>
<p><span class="Italics">Liver and Biliary System: </span> hepatic enzyme increase, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>. A few of the postmarketing reports of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, including cases in patients with no pre-existing <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> or other identifiable risk factors, were characterized by a fulminant course, progressing in some cases to transplantation or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p><span class="Italics">Metabolic and
Nutritional: </span> <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span></p>
<p><span class="Italics">Musculoskeletal: </span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> </p>
<p><span class="Italics">Psychiatric: </span> <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive reactions</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>,
<span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusions</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, <span class="product-label-link" type="condition" conceptid="444243" conceptname="Neurosis">neurosis</span>, <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></p>
<p><span class="Italics">Respiratory: </span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> </p>
<p><span class="Italics">Skin
and Appendages: </span> <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, photoallergic <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, Stevens-Johnson
syndrome</p>
<p><span class="Italics">Special Senses: </span> abnormal
vision, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7     DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1     Drug-Drug Interactions</h2>
<p class="First">Efavirenz has been shown <span class="Italics"> in
vivo</span> to induce CYP3A and CYP2B6. Other compounds that are substrates of CYP3A or CYP2B6
may have decreased plasma concentrations when coadministered with SUSTIVA. <span class="Italics">In
vitro</span> studies have demonstrated that efavirenz inhibits CYP2C9, 2C19,
and 3A4 isozymes in the range of observed efavirenz plasma concentrations.
Coadministration of efavirenz with drugs primarily metabolized by these isozymes
may result in altered plasma concentrations of the coadministered drug. Therefore,
appropriate dose adjustments may be necessary for these drugs.</p>
<p>Drugs that induce CYP3A activity (eg, phenobarbital, rifampin,
rifabutin) would be expected to increase the clearance of efavirenz resulting
in lowered plasma concentrations. Drug interactions with SUSTIVA are summarized
in <a href="#table2">Tables 2 </a> and <a href="#table7"> 7 </a>[for
pharmacokinetics data see <span class="Italics">Clinical Pharmacology <a href="#Section_12.3"> (12.3</a>,
 <a href="#table8"> Tables 8 </a></span>and<span class="Italics"><a href="#table9"> 9)</a></span>].
The tables include potentially significant interactions, but are not all inclusive.</p>
<a name="table7"></a><table width="100%">
<caption><span>Table 7:	Established and Other Potentially Significant Drug
Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug
Interaction Studies or Predicted Interaction</span></caption>
<col width="25%">
<col width="20%">
<col width="55%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" colspan="1" rowspan="1" valign="bottom"><span class="Bold">Concomitant
Drug Class: Drug Name</span></th>
<th class="Botrule Toprule" align="center" colspan="1" rowspan="1" valign="bottom"><span class="Bold">Effect</span></th>
<th class="Botrule Toprule" align="center" colspan="1" rowspan="1" valign="bottom"><span class="Bold">Clinical
Comment</span></th>
</tr></thead>
<tfoot>
<tr class="First"><td colspan="3" rowspan="1">
<span class="Sup">*</span>  The interaction between SUSTIVA and the drug was evaluated in a clinical study. All other drug interactions shown are predicted.</td></tr>
<tr class="Last"><td colspan="3" rowspan="1">This table is not all-inclusive.</td></tr>
</tfoot>
<tbody>
<tr class="Botrule First"><td colspan="3" rowspan="1"><span class="Italics">HIV antiviral agents</span></td></tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">Protease inhibitor:<br>Â Fosamprenavir<br>Â calcium</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â amprenavir</td>
<td align="left" colspan="1" rowspan="1">Fosamprenavir
(unboosted): Appropriate doses of the combinations with respect to safety
and efficacy have not been established.<br>Fosamprenavir/ritonavir:
An additional 100 mg/day (300 mg total) of ritonavir is recommended when SUSTIVA
is administered with fosamprenavir/ritonavir once daily. No change in the
ritonavir dose is required when SUSTIVA is administered with fosamprenavir
plus ritonavir twice daily.</td>
</tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">Protease inhibitor:<br>Â Atazanavir sulfate</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â atazanavir<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">
<span class="Italics"> Treatment-naive patients:  </span>  When coadministered with SUSTIVA, the recommended dose of atazanavir is 400 mg with ritonavir 100 mg (together once daily with food) and SUSTIVA 600 mg (once daily on an empty stomach, preferably at bedtime).<br><span class="Italics">Treatment-experienced patients:  </span>  Coadministration of SUSTIVA and atazanavir is not recommended.</td>
</tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">Protease inhibitor:<br>Â Indinavir</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â indinavir<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">The optimal dose
of indinavir, when given in combination with SUSTIVA, is not known. Increasing
the indinavir dose to 1000Â mg every 8 hours does not compensate for the increased
indinavir metabolism due to SUSTIVA. When indinavir at an increased dose (1000Â mg
every 8 hours) was given with SUSTIVA (600Â mg once daily), the indinavir AUC
and C<span class="Sub">min</span> were decreased on average by 33-46% and 39-57%,
respectively, compared to when indinavir (800Â mg every 8 hours) was given
alone.</td>
</tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">Protease inhibitor:<br>Â Lopinavir/ritonavir</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â lopinavir<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">Lopinavir/ritonavir
tablets should not be administered once daily in combination with SUSTIVA.
In antiretroviral-naive patients, lopinavir/ritonavir tablets can be used
twice daily in combination with SUSTIVA with no dose adjustment. A dose increase
of lopinavir/ritonavir tablets to 600/150Â mg (3Â tablets) twice daily may be
considered when used in combination with SUSTIVA in treatment-experienced
patients where decreased susceptibility to lopinavir is clinically suspected
(by treatment history or laboratory evidence). A dose increase of lopinavir/ritonavir
oral solution to 533/133Â mg (6.5Â mL) twice daily taken with food is recommended
when used in combination with SUSTIVA.</td>
</tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">Protease inhibitor:<br>Â Ritonavir	</td>
<td align="center" colspan="1" rowspan="1">
<br>â†‘Â ritonavir<span class="Sup">*</span><br>â†‘Â efavirenz<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">When ritonavir
500 mg q12h was coadministered with SUSTIVA 600 mg once daily, the combination
was associated with a higher frequency of adverse clinical experiences (eg,
<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>) and laboratory abnormalities (elevated liver
enzymes).  Monitoring of liver enzymes is recommended when SUSTIVA is used
in combination with ritonavir.</td>
</tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">Protease inhibitor:<br>Â Saquinavir	</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â saquinavir<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">Should not be used as sole protease inhibitor in combination with SUSTIVA.</td>
</tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">NNRTI:<br>Â Other NNRTIs	</td>
<td align="center" colspan="1" rowspan="1">â†‘Â or â†“Â efavirenz<br>and/or NNRTI
											</td>
<td align="left" colspan="1" rowspan="1">Combining two NNRTIs has not been shown to be beneficial. SUSTIVA should not be coadministered with other NNRTIs.</td>
</tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">CCR5 co-receptor antagonist:<br>Â Maraviroc	</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â maraviroc<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">Refer to the full prescribing information for maraviroc for guidance on coadministration with efavirenz.</td>
</tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">Integrase strand transfer inhibitor:<br>Â Raltegravir	</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â raltegravir<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">SUSTIVA reduces plasma concentrations of raltegravir. The clinical significance of this interaction has not been directly assessed.
											</td>
</tr>
<tr class="Botrule"><td colspan="3" rowspan="1"><span class="Italics"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C antiviral agents</span></td></tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">Protease inhibitor:<br>Â Boceprevir	</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â boceprevir<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">Plasma trough concentrations of boceprevir were decreased when boceprevir was coadministered with SUSTIVA, which may result in loss of therapeutic effect. The combination should be avoided.
											</td>
</tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">Protease inhibitor:<br>Â Telaprevir	</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â telaprevir<span class="Sup">*</span><br>â†“Â efavirenz<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">Concomitant administration of telaprevir and SUSTIVA resulted in reduced steady-state exposures to telaprevir and efavirenz.
											</td>
</tr>
<tr class="Botrule"><td colspan="3" rowspan="1"><span class="Italics">Other agents</span></td></tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">Anticoagulant:<br>Â Warfarin</td>
<td align="center" colspan="1" rowspan="1">
<br>â†‘Â orÂ â†“Â warfarin</td>
<td align="left" colspan="1" rowspan="1">Plasma concentrations
and effects potentially increased or decreased by SUSTIVA.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Anticonvulsants:<br>Â Carbamazepine</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â carbamazepine<span class="Sup">*</span><br>â†“Â efavirenz<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">
<br>There are insufficient
data to make a dose recommendation for efavirenz. Alternative anticonvulsant
treatment should be used.</td>
</tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">Â Phenytoin<br>Â Phenobarbital</td>
<td align="center" colspan="1" rowspan="1">â†“Â anticonvulsant<br>â†“Â efavirenz</td>
<td align="left" colspan="1" rowspan="1">Potential for
reduction in anticonvulsant and/or efavirenz plasma levels; periodic monitoring
of anticonvulsant plasma levels should be conducted.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Antidepressants:<br>Â Bupropion</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â bupropion<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">
<br>The effect of efavirenz on bupropion exposure is thought to be due to the induction of bupropion metabolism. Increases in bupropion dosage should be guided by clinical response, but the maximum recommended dose of bupropion should not be exceeded.</td>
</tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">Â Sertraline</td>
<td align="center" colspan="1" rowspan="1">â†“Â sertraline<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">Increases in sertraline
dosage should be guided by clinical response.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Antifungals:<br>Â Voriconazole</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â voriconazole<span class="Sup">*</span><br>â†‘Â efavirenz<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">
<br>SUSTIVA and voriconazole
must not be coadministered at standard doses. Efavirenz significantly decreases
voriconazole plasma concentrations, and coadministration may decrease the
therapeutic effectiveness of voriconazole. Also, voriconazole significantly
increases efavirenz plasma concentrations, which may increase the risk of
SUSTIVA-associated side effects. When voriconazole is coadministered with
SUSTIVA, voriconazole maintenance dose should be increased to 400Â mg every
12Â hours and SUSTIVA dose should be decreased to 300Â mg once daily using the
capsule formulation. SUSTIVA tablets should not be broken. [See <span class="Italics">Dosage
and Administration <a href="#Section_2.1"> (2.1) </a></span> and <span class="Italics">Clinical
Pharmacology <a href="#Section_12.3"> (12.3</a>, <a href="#table8"> Tables 8 </a></span> and <span class="Italics"><a href="#table9"> 9)</a></span>.]</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<br>Â Itraconazole</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â itraconazole<span class="Sup">*</span><br>â†“Â hydroxyitraconazole<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">
<br>Since no dose recommendation
for itraconazole can be made, alternative antifungal treatment should be considered.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Ketoconazole</td>
<td align="center" colspan="1" rowspan="1">â†“Â ketoconazole</td>
<td align="left" colspan="1" rowspan="1">Drug interaction
studies with SUSTIVA and ketoconazole have not been conducted. SUSTIVA has
the potential to decrease plasma concentrations of ketoconazole.</td>
</tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">Â Posaconazole</td>
<td align="center" colspan="1" rowspan="1">â†“Â posaconazole<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">Avoid concomitant use unless the benefit outweighs the risks.
											</td>
</tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">Anti-infective:<br>Â Clarithromycin	</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â clarithromycin<span class="Sup">*</span><br>â†‘Â 14-OH
metabolite<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">Plasma concentrations
decreased by SUSTIVA; clinical significance unknown. In uninfected volunteers,
46% developed <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> while receiving SUSTIVA and clarithromycin. No dose adjustment
of SUSTIVA is recommended when given with clarithromycin. Alternatives to
clarithromycin, such as azithromycin, should be considered (see <span class="Italics"><a href="#Section_7.1.1">Other Drugs</a></span>, following table). Other
macrolide antibiotics, such as erythromycin, have not been studied in combination
with SUSTIVA.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Antimycobacterials:<br>Â Rifabutin	</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â rifabutin<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">Increase daily dose of rifabutin
by 50%. Consider doubling the rifabutin dose in regimens where rifabutin is
given 2 or 3 times a week.</td>
</tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">Â Rifampin	</td>
<td align="center" colspan="1" rowspan="1">â†“Â efavirenz<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">If SUSTIVA is coadministered with rifampin to patients weighing 50 kg or more, an increase in the dose of SUSTIVA to 800 mg once daily is recommended.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Calcium channel blockers:<br>Â Diltiazem</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â diltiazem<span class="Sup">*</span><br>â†“Â desacetyl diltiazem<span class="Sup">*</span><br>â†“Â N-monodesmethyl diltiazem<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">Diltiazem dose adjustments should
be guided by clinical response (refer to the full prescribing information
for diltiazem). No dose adjustment of efavirenz is necessary when administered
with diltiazem.</td>
</tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">Others (eg, felodipine,
nicardipine, nifedipine, verapamil)</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â calcium
channel blocker</td>
<td align="left" colspan="1" rowspan="1">No data are available
on the potential interactions of efavirenz with other calcium channel blockers
that are substrates of CYP3A. The potential exists for reduction in plasma
concentrations of the calcium channel blocker. Dose adjustments should be
guided by clinical response (refer to the full prescribing information
for the calcium channel blocker).</td>
</tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">HMG-CoA reductase
inhibitors:<br>Â Â Atorvastatin <br>Â Â Pravastatin<br>Â Â Simvastatin</td>
<td align="center" colspan="1" rowspan="1">
<br><br>Â Â â†“Â atorvastatin<span class="Sup">*</span><br>â†“Â pravastatin<span class="Sup">*</span><br>â†“Â simvastatin<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">Plasma concentrations
of atorvastatin, pravastatin, and simvastatin decreased. Consult the full
prescribing information for the HMG-CoA reductase inhibitor for guidance on
individualizing the dose.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Hormonal contraceptives: <br>Oral<br>Â Ethinyl
estradiol/<br>Â Norgestimate</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â active metabolites<br>of norgestimate<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">
<br>A reliable method of barrier contraception must be used in addition to hormonal contraceptives. Efavirenz had no effect on ethinyl estradiol concentrations, but progestin levels (norelgestromin and levonorgestrel) were markedly decreased. No effect of ethinyl estradiol/norgestimate on efavirenz plasma concentrations was observed. 
											</td>
</tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">Implant<br>Â Etonogestrel</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â etonogestrel</td>
<td align="left" colspan="1" rowspan="1">
<br>A reliable method of barrier contraception must be used in addition to hormonal contraceptives. The interaction between etonogestrel and efavirenz has not been studied.  Decreased exposure of etonogestrel may be expected. There have been postmarketing reports of contraceptive failure with etonogestrel in efavirenz-exposed patients. </td>
</tr>
<tr class="Botrule" valign="top">
<td align="left" colspan="1" rowspan="1">Immunosuppressants: <br>Cyclosporine, tacrolimus, sirolimus, and others metabolized by CYP3A</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â immunosuppressant
											</td>
<td align="left" colspan="1" rowspan="1">Decreased exposure of the immunosuppressant may be expected due to CYP3A induction. These immunosuppressants are not anticipated to affect exposure of efavirenz. Dose adjustments of the immunosuppressant may be required. Close monitoring of immunosuppressant concentrations for at least 2 weeks (until stable concentrations are reached) is recommended when starting or stopping treatment with efavirenz. 
											</td>
</tr>
<tr class="Botrule Last" valign="top">
<td align="left" colspan="1" rowspan="1">Narcotic analgesic:<br>Â Methadone</td>
<td align="center" colspan="1" rowspan="1">
<br>â†“Â methadone<span class="Sup">*</span>
</td>
<td align="left" colspan="1" rowspan="1">Coadministration
in HIV-infected individuals with a history of injection drug use resulted
in decreased plasma levels of methadone and signs of opiate withdrawal.  Methadone
dose was increased by a mean of 22% to alleviate withdrawal symptoms.  Patients
should be monitored for signs of withdrawal and their methadone dose increased
as required to alleviate withdrawal symptoms.</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7.1.1"></a><a name="section-7.1.1"></a><p></p>
<h3 class="Bold">Other Drugs </h3>
<p class="First">Based on the results of drug interaction
studies [see <span class="Italics">Clinical Pharmacology <a href="#Section_12.3"> (12.3</a>,
 <a href="#table8"> Tables 8</a></span> and <span class="Italics"><a href="#table9"> 9)</a></span>],
no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with
the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine,
famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, tenofovir
disoproxil fumarate, and zidovudine.   </p>
<p>Specific
drug interaction studies have not been performed with SUSTIVA and NRTIs other
than lamivudine and zidovudine. Clinically significant interactions would
not be expected since the NRTIs are metabolized via a different route than
efavirenz and would be unlikely to compete for the same metabolic enzymes
and elimination pathways.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2     Cannabinoid Test Interaction</h2>
<p class="First">Efavirenz does not bind to cannabinoid
receptors. False-positive urine cannabinoid test results have been observed
in non-HIV-infected volunteers receiving SUSTIVA when the Microgenics CEDIA
DAU Multi-Level THC assay was used for screening. Negative results were obtained
when more specific confirmatory testing was performed with gas chromatography/<span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span>
spectrometry.</p>
<p>Of the three assays analyzed (Microgenics
CEDIA DAU Multi-Level THC assay, Cannabinoid Enzyme Immunoassay [Diagnostic
Reagents, Inc], and AxSYM Cannabinoid Assay), only the Microgenics CEDIA DAU
Multi-Level THC assay showed false-positive results. The other two assays
provided true-negative results. The effects of SUSTIVA on cannabinoid screening
tests other than these three are unknown. The manufacturers of cannabinoid
assays should be contacted for additional information regarding the use of
their assays with patients receiving efavirenz.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8     USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1     Pregnancy</h2>
<p class="First"> Pregnancy Category D:  See <span class="Italics">Warnings and Precautions <a href="#Section_5.6"> (5.6)</a></span>.</p>
<p><span class="Bold">Antiretroviral Pregnancy Registry: </span> To monitor fetal
outcomes of pregnant women exposed to SUSTIVA, an Antiretroviral Pregnancy
Registry has been established. Physicians are encouraged to register patients
by calling 1-800-258-4263.</p>
<p>As of July 2010, the
Antiretroviral Pregnancy Registry has received prospective reports of 792
pregnancies exposed to efavirenz-containing regimens, nearly all of which
were first-trimester exposures (718 pregnancies). <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth defects</span> occurred in
17 of 604 live births (first-trimester exposure) and 2 of 69 live births (second/third-trimester
exposure). One of these prospectively reported defects with first-trimester exposure was a <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defect</span>. A single case of <span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span> with first-trimester exposure to efavirenz has also been prospectively reported; however, this case included severe oblique facial clefts and amniotic banding, a known association with <span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span>. There have been six retrospective reports of findings consistent
with <span class="product-label-link" type="condition" conceptid="4102400" conceptname="Neural tube defect">neural tube defects</span>, including <span class="product-label-link" type="condition" conceptid="4212197" conceptname="Meningomyelocele">meningomyelocele</span>. All mothers were exposed
to efavirenz-containing regimens in the first trimester. Although a causal
relationship of these events to the use of SUSTIVA has not been established,
similar defects have been observed in preclinical studies of efavirenz.
								</p>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1.1"></a><a name="section-8.1.1"></a><p></p>
<h3 class="Bold">Animal Data</h3>
<p class="First">Effects of efavirenz on embryo-fetal development have been studied in three nonclinical species (cynomolgus monkeys, rats, and rabbits). In monkeys, efavirenz 60 mg/kg/day was administered to pregnant females throughout pregnancy (gestation days 20 through 150). The maternal systemic drug exposures (AUC) were 1.3 times the exposure in humans at the recommended clinical dose (600 mg/day), with fetal umbilical venous drug concentrations approximately 0.7 times the maternal values. Three fetuses of 20 fetuses/infants had one or more malformations; there were no malformed fetuses or infants from placebo-treated mothers. The malformations that occurred in these three monkey fetuses included <span class="product-label-link" type="condition" conceptid="377368" conceptname="Anencephalus">anencephaly</span> and unilateral <span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span> in one fetus, microophthalmia in a second, and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> in the third. There was no NOAEL (no observable adverse effect level) established for this study because only one dosage was evaluated. In rats, efavirenz was administered either during organogenesis (gestation days 7 to 18) or from gestation day 7 through lactation day 21 at 50, 100, or 200 mg/kg/day.  Administration of 200 mg/kg/day in rats was associated with increase in the incidence of early resorptions; and doses 100 mg/kg/day and greater were associated with early neonatal mortality. The AUC at the NOAEL (50 mg/kg/day) in this rat study was 0.1 times that in humans at the recommended clinical dose. Drug concentrations in the milk on lactation day 10 were approximately 8 times higher than those in maternal plasma. In pregnant rabbits, efavirenz was neither embryo lethal nor teratogenic when administered at doses of 25, 50, and 75 mg/kg/day over the period of organogenesis (gestation days 6 through 18). The AUC at the NOAEL (75 mg/kg/day) in rabbits was 0.4 times that in humans at the recommended clinical dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3     Nursing Mothers</h2>
<p class="First"> The Centers for  Disease Control
and Prevention recommend that HIV-infected mothers not  breast-feed their
infants to avoid risking postnatal transmission of HIV. Although it is not
known if efavirenz is secreted in human milk, efavirenz is secreted into the
milk of lactating rats. Because of the potential for HIV transmission and
the potential for serious adverse effects in nursing infants, mothers should
be instructed not to breast-feed if they are receiving SUSTIVA.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4     Pediatric Use</h2>
<p class="First">ACTG 382 is an ongoing, open-label
study in 57 NRTI-experienced pediatric patients to characterize the safety,
pharmacokinetics, and antiviral activity of SUSTIVA in combination with nelfinavir
(20-30 mg/kg three times daily) and NRTIs. Mean age was 8 years (range 3-16).
SUSTIVA has not been studied in pediatric patients below 3 years of age or
who weigh less than 13 kg. At 48 weeks, the type and frequency of adverse
experiences was generally similar to that of adult patients with the exception
of a higher incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, which was reported in 46% (26/57) of pediatric
patients compared to 26% of adults, and a higher frequency of Grade 3 or 4
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> reported in 5% (3/57) of pediatric patients compared to 0.9% of adults
[see <span class="Italics">Warnings and Precautions <a href="#Section_5.7"> (5.7) </a></span> and <span class="Italics">Adverse
Reactions <a href="#Section_6.1"> (6.1</a>, <a href="#table5"> Table 5</a>; <a href="#Section_6.2"> 6.2)</a></span>].</p>
<p>The starting dose of SUSTIVA was
600 mg once daily adjusted to body size, based on weight, targeting AUC levels
in the range of 190-380 ÂµMâ€¢h [see <span class="Italics">Dosage and Administration <a href="#Section_2.2"> (2.2)</a></span>]. The pharmacokinetics of efavirenz
in pediatric patients were similar to the pharmacokinetics in adults who received
600-mg daily doses of SUSTIVA. In 48 pediatric patients receiving the equivalent
of a 600-mg dose of SUSTIVA, steady-state C<span class="Sub">max</span> was
14.2 Â± 5.8 ÂµM (mean Â± SD), steady-state C<span class="Sub">min</span> was 5.6 Â± 4.1 ÂµM, and AUC was 218 Â± 104 ÂµMâ€¢h.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5     Geriatric Use</h2>
<p class="First">Clinical studies of SUSTIVA did
not include sufficient numbers of subjects aged 65 years and over to determine
whether they respond differently from younger subjects. In general, dose selection
for an elderly patient should be cautious, reflecting the greater frequency
of decreased hepatic, renal, or cardiac function and of concomitant disease
or other therapy.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6     <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">SUSTIVA is not recommended for patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> because there are insufficient data to determine whether dose adjustment is necessary. Patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> may be treated with efavirenz without any adjustment in dose. Because of the extensive cytochrome P450-mediated metabolism of efavirenz and limited clinical experience in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, caution should be exercised in administering SUSTIVA to these patients [see <span class="Italics">Warnings and Precautions <a href="#Section_5.8"> (5.8)</a></span> and <span class="Italics">Clinical Pharmacology <a href="#Section_12.3"> (12.3)</a></span>].
								</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10     OVERDOSAGE</h1>
<p class="First">Some patients accidentally taking
600 mg twice daily have reported increased nervous system symptoms. One patient
experienced involuntary muscle contractions.</p>
<p>Treatment
of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with SUSTIVA should consist of general supportive measures, including
monitoring of vital signs and observation of the patientâ€™s clinical status.
Administration of activated charcoal may be used to aid removal of unabsorbed
drug. There is no specific antidote for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with SUSTIVA. Since efavirenz
is highly protein bound, dialysis is unlikely to significantly remove the
drug from blood.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11     DESCRIPTION</h1>
<p class="First">SUSTIVA<span class="Sup">Â®</span> (efavirenz)
is an HIV-1 specific, non-nucleoside, reverse transcriptase inhibitor (NNRTI).
Efavirenz is chemically described as (S)-6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one.
Its empirical formula is C<span class="Sub">14</span>H<span class="Sub">9</span>ClF<span class="Sub">3</span>NO<span class="Sub">2</span> and
its structural formula is:</p>
<div class="Figure"><img alt="efavirenz chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=04b5c345-c446-43a4-83f0-509bc287e10b&amp;name=sustiva-structure1.jpg"></div>
<p>Efavirenz is a white to slightly pink crystalline powder
with a molecular <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> of 315.68. It is practically insoluble in water (&lt;10
microgram/mL).</p>
<p><span class="Italics">Capsules:</span> SUSTIVA is
available as capsules for oral administration containing either 50 mg or 200 mg of efavirenz and the following inactive ingredients: lactose monohydrate,
magnesium stearate, sodium lauryl sulfate, and sodium starch glycolate. The
capsule shell contains the following inactive ingredients and dyes: gelatin,
sodium lauryl sulfate, titanium dioxide, and/or yellow iron oxide. The capsule
shells may also contain silicon dioxide. The capsules are printed with ink
containing carmine 40 blue, FD&amp;C Blue No. 2, and titanium dioxide.</p>
<p><span class="Italics">Tablets:</span> SUSTIVA
is available as film-coated tablets for oral administration containing 600
mg of efavirenz and the following inactive ingredients: croscarmellose sodium,
hydroxypropyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline
cellulose, and sodium lauryl sulfate. The film coating contains Opadry Yellow
and Opadry Clear. The tablets are polished with carnauba wax and printed with
purple ink, Opacode WB.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12     CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1     Mechanism of Action</h2>
<p class="First">Efavirenz is an antiviral drug
[see <span class="Italics">Clinical Pharmacology <a href="#Section_12.4"> (12.4)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3     Pharmacokinetics</h2>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3.1"></a><a name="section-11.2.1"></a><p></p>
<h3 class="Bold">Absorption</h3>
<p class="First">Peak efavirenz plasma concentrations
of 1.6-9.1 Î¼M were attained by 5 hours following single oral doses of 100
mg to 1600 mg administered to uninfected volunteers. Dose-related increases
in C<span class="Sub">max</span> and AUC were seen for doses up to 1600 mg;
the increases were less than proportional suggesting diminished absorption
at higher doses. </p>
<p>In HIV-1-infected patients at
steady state, mean C<span class="Sub">max</span>, mean C<span class="Sub">min</span>,
and mean AUC were dose proportional following 200-mg, 400-mg, and 600-mg daily
doses. Time-to-peak plasma concentrations were approximately 3-5 hours and
steady-state plasma concentrations were reached in 6-10 days. In 35 patients
receiving SUSTIVA 600 mg once daily, steady-state C<span class="Sub">max</span> was
12.9 Â± 3.7 Î¼M (mean Â± SD), steady-state C<span class="Sub">min</span> was 5.6 Â± 3.2 Î¼M, and AUC was 184 Â±Â 73 Î¼Mâ€¢h.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3.1.1"></a><a name="section-11.2.1.1"></a><p></p>
<h4 class="Bold">Effect of Food on Oral Absorption:</h4>
<p class="First"><span class="Italics">Capsules: </span>  Administration
of a single 600-mg dose of efavirenz capsules with a high-fat/high-caloric
meal (894 kcal, 54 g fat, 54% calories from fat) or a reduced-fat/normal-caloric
meal (440 kcal, 2 g fat, 4% calories from fat) was associated with a mean
increase of 22% and 17% in efavirenz AUC<span class="Sub">âˆž</span> and a mean
increase of 39% and 51% in efavirenz C<span class="Sub">max</span>, respectively,
relative to the exposures achieved when given under fasted conditions. See <span class="Italics">Dosage
and Administration <a href="#Section_2"> (2)</a></span> and <span class="Italics">Patient
Counseling Information <a href="#Section_17.3"> (17.3)</a></span>.</p>
<p><span class="Italics">Tablets: </span>  Administration of a single 600-mg efavirenz
tablet with a high-fat/high-caloric meal (approximately 1000 kcal, 500-600
kcal from fat) was associated with a 28% increase in mean AUC<span class="Sub">âˆž</span> of
efavirenz and a 79% increase in mean C<span class="Sub">max</span> of efavirenz
relative to the exposures achieved under fasted conditions. See <span class="Italics">Dosage
and Administration <a href="#Section_2"> (2)</a></span> and <span class="Italics">Patient
Counseling Information <a href="#Section_17.3"> (17.3)</a></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3.3"></a><a name="section-11.2.2"></a><p></p>
<h3 class="Bold">Distribution</h3>
<p class="First">Efavirenz is highly bound (approximately
99.5-99.75%) to human plasma proteins, predominantly albumin. In HIV-1 infected
patients (n=9) who received SUSTIVA 200 to 600 mg once daily for at least
one month, cerebrospinal fluid concentrations ranged from 0.26 to 1.19% (mean
0.69%) of the corresponding plasma concentration. This proportion is approximately
3-fold higher than the non-protein-bound (free) fraction of efavirenz in plasma.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3.4"></a><a name="section-11.2.3"></a><p></p>
<h3 class="Bold">Metabolism</h3>
<p class="First">Studies in humans and <span class="Italics">in vitro </span> studies
using human liver microsomes have demonstrated that efavirenz is principally
metabolized by the cytochrome P450 system to hydroxylated metabolites with
subsequent glucuronidation of these hydroxylated metabolites. These metabolites
are essentially inactive against HIV-1. The <span class="Italics">in vitro</span> studies
suggest that CYP3A and CYP2B6 are the major isozymes responsible for efavirenz
metabolism. </p>
<p>Efavirenz has been shown to induce
CYP enzymes, resulting in the induction of its own metabolism. Multiple doses
of 200-400 mg per day for 10 days resulted in a lower than predicted extent
of accumulation (22-42% lower) and a shorter terminal half-life of 40-55 hours
(single dose half-life 52-76 hours). </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3.5"></a><a name="section-11.2.4"></a><p></p>
<h3 class="Bold">Elimination</h3>
<p class="First">Efavirenz has a terminal half-life
of 52-76 hours after single doses and 40-55 hours after multiple doses. A
one-month <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance/excretion study was conducted using 400 mg per day
with a <span class="Sup">14</span>C-labeled dose administered on Day 8.
Approximately 14-34% of the radiolabel was recovered in the urine and 16-61%
was recovered in the feces. Nearly all of the urinary excretion of the radiolabeled
drug was in the form of metabolites. Efavirenz accounted for the majority
of the total radioactivity measured in feces.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3.6"></a><a name="section-11.2.5"></a><p></p>
<h3 class="Bold">Special Populations</h3>
<p class="First"><span class="Italics">Gender and race:  </span> The
pharmacokinetics of efavirenz in patients appear to be similar between men
and women and among the racial groups studied.</p>
<p><span class="Italics">Renal
impairment: </span> The pharmacokinetics of efavirenz have not been studied
in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>; however, less than 1% of efavirenz is
excreted unchanged in the urine, so the impact of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on efavirenz
elimination should be minimal.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>:</span> A multiple-dose study showed no significant effect on efavirenz pharmacokinetics in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class A) compared with controls. There were insufficient data to determine whether moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class B or C) affects efavirenz pharmacokinetics.
										</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3.7"></a><a name="section-11.2.6"></a><p></p>
<h3 class="Bold">Drug Interaction Studies</h3>
<p class="First">Efavirenz has been shown <span class="Italics">in
vivo</span> to cause hepatic enzyme induction, thus increasing the biotransformation
of some drugs metabolized by CYP3A and CYP2B6. <span class="Italics">In vitro</span> studies have
shown that efavirenz inhibited CYP isozymes 2C9, 2C19, and 3A4 with K<span class="Sub">i </span> values
(8.5-17 Î¼M) in the range of observed efavirenz plasma concentrations. In <span class="Italics">in
vitro</span> studies, efavirenz did not inhibit CYP2E1 and inhibited CYP2D6
and CYP1A2 (K<span class="Sub">i </span> values 82-160 Î¼M) only at concentrations
well above those achieved clinically. The inhibitory effect on CYP3A is expected
to be similar between 200-mg, 400-mg, and 600-mg doses of efavirenz. Coadministration
of efavirenz with drugs primarily metabolized by 2C9, 2C19, and 3A isozymes
may result in altered plasma concentrations of the coadministered drug. Drugs
which induce CYP3A activity would be expected to increase the clearance of
efavirenz resulting in lowered plasma concentrations.</p>
<p>Drug
interaction studies were performed with efavirenz and other drugs likely to
be coadministered or drugs commonly used as probes for <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span>.
The effects of coadministration of efavirenz on the C<span class="Sub">max</span>,
AUC, and C<span class="Sub">min</span> are summarized in <a href="#table8"> Table 8</a> (effect of
efavirenz on other drugs) and <a href="#table9"> Table 9</a> (effect of other drugs on efavirenz).
For information regarding clinical recommendations see <span class="Italics">Contraindications <a href="#Section_4.2"> (4.2)</a></span> and <span class="Italics">Drug Interactions <a href="#Section_7.1"> (7.1)</a></span>.</p>
<a name="table8"></a><table width="100%">
<caption><span>Table 8:	Effect of Efavirenz on Coadministered Drug Plasma C<span class="Sub">max</span>,
AUC, and C<span class="Sub">min</span></span></caption>
<col width="12%">
<col width="20%">
<col width="20%">
<col width="5%">
<col width="14%">
<col width="15%">
<col width="14%">
<thead>
<tr class="First">
<th class="Toprule" align="left" rowspan="2" valign="bottom"><span class="Bold">Coadministered
Drug</span></th>
<th class="Toprule" align="center" rowspan="2" valign="bottom"><span class="Bold">Dose</span></th>
<th class="Toprule" align="center" rowspan="2" valign="bottom"><span class="Bold">Efavirenz
Dose</span></th>
<th class="Toprule" rowspan="2" valign="bottom"><span class="Bold">Number of Subjects</span></th>
<th class="Botrule Toprule" align="center" colspan="3" rowspan="1"><span class="Bold">Coadministered
Drug<br>(mean % change)</span></th>
</tr>
<tr class="Last" valign="bottom">
<th class="Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">C<span class="Sub">max</span><br>(90%
CI)</span></th>
<th class="Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">AUC<br>(90%
CI)</span></th>
<th class="Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">C<span class="Sub">min</span><br>(90%
CI)</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="7">â†‘ Indicates increaseÂ Â Â  â†“ Indicates decreaseÂ Â Â â†”  Indicates no change or a mean increase or decrease of &lt;10%.</td></tr>
<tr><td colspan="7">
<span class="Sup">a</span>Â Â Compared with atazanavir 400
mg qd alone.</td></tr>
<tr><td colspan="7">
<span class="Sup">b</span>Â Â Comparator dose of indinavir
was 800 mg q8h x 10 days.</td></tr>
<tr><td colspan="7">
<span class="Sup">c</span>Â Â Parallel-group design; n for
efavirenz + lopinavir/ritonavir, n for lopinavir/ritonavir alone.</td></tr>
<tr><td colspan="7">
<span class="Sup">d</span>Â Â Values are for lopinavir;
the pharmacokinetics of ritonavir in this study were unaffected by concurrent
efavirenz.</td></tr>
<tr><td colspan="7">
<span class="Sup">e</span> 95% CI.</td></tr>
<tr><td colspan="7">
<span class="Sup">f</span>Â Â Soft Gelatin Capsule.</td></tr>
<tr><td colspan="7">
<span class="Sup">g</span>Â Â Tenofovir disoproxil fumarate.</td></tr>
<tr><td colspan="7">
<span class="Sup">h</span>Â Â 90% CI not available.</td></tr>
<tr><td colspan="7">
<span class="Sup">i</span>Â Â Relative to steady-state administration
of voriconazole (400 mg for 1 day, then 200 mg po q12h for 2 days).</td></tr>
<tr><td align="left" colspan="7">
<span class="Sup">j</span>Â Â Not available because
of insufficient data.</td></tr>
<tr class="Last"><td colspan="7">NA = not available.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Toprule" colspan="1" rowspan="1" valign="top">Atazanavir</td>
<td class="Toprule" colspan="1" rowspan="1" valign="top">400 mg qd with a
light meal dÂ 1â€‘20</td>
<td class="Toprule" colspan="1" rowspan="1" valign="top">600 mg qd with a
light meal dÂ 7â€‘20</td>
<td class="Toprule" align="center" colspan="1" rowspan="1" valign="top">27</td>
<td class="Toprule" align="center" colspan="1" rowspan="1" valign="top">â†“Â 59%<br>(49-67%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1" valign="top">â†“Â 74%<br>(68-78%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1" valign="top">â†“Â 93%<br>(90-95%)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Â </td>
<td colspan="1" rowspan="1" valign="top">400 mg qd dÂ 1â€‘6, then 300Â mg qd dÂ 7â€‘20 with ritonavir 100Â mg qd and a light meal</td>
<td colspan="1" rowspan="1" valign="top">600 mg qd 2 h after atazanavir and
ritonavir dÂ 7â€‘20</td>
<td align="center" colspan="1" rowspan="1" valign="top">13</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†‘Â 14%<span class="Sup">a</span><br>(â†“Â 17-â†‘Â 58%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†‘Â 39%<span class="Sup">a</span><br>(2-88%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†‘Â 48%<span class="Sup">a</span><br>(24-76%)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Â </td>
<td colspan="1" rowspan="1" valign="top">300Â mg qd/ritonavir 100Â mg qd dÂ 1â€‘10 (pm), then 400Â mg qd/ritonavir 100Â mg qd dÂ 11â€‘24 (pm) (simultaneous with efavirenz)</td>
<td colspan="1" rowspan="1" valign="top">600Â mg qd with a light snack dÂ 11â€‘24 (pm)</td>
<td align="center" colspan="1" rowspan="1" valign="top">14</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†‘Â 17%<br>(8-27%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†”</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†“Â 42%
														<br>(31-51%)</td>
</tr>
<tr>
<td class="Toprule" colspan="1" rowspan="1" valign="top">Indinavir</td>
<td class="Toprule" colspan="1" rowspan="1">1000 mg q8h x 10 days</td>
<td class="Toprule" colspan="1" rowspan="1">600 mg qd x 10 days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">20</td>
<td class="Toprule" align="left" colspan="3" rowspan="1">Â </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â </td>
<td colspan="3" rowspan="1" valign="top">After morning dose</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†”<span class="Sup">b</span>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†“Â 33%<span class="Sup">b</span><br>(26-39%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†“Â 39%<span class="Sup">b</span><br>(24-51%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â </td>
<td colspan="3" rowspan="1" valign="top">After afternoon dose</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†”<span class="Sup">b</span>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†“Â 37%<span class="Sup">b</span><br>(26-46%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†“Â 52%<span class="Sup">b</span><br>(47-57%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â </td>
<td colspan="3" rowspan="1" valign="top">After evening dose</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†“ 29%<span class="Sup">b</span><br>(11-43%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†“Â 46%<span class="Sup">b</span><br>(37-54%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†“Â 57%<span class="Sup">b</span><br>(50-63%)</td>
</tr>
<tr valign="top">
<td class="Toprule" colspan="1" rowspan="1">Lopinavir/<br>Â Â Â ritonavir</td>
<td class="Toprule" colspan="1" rowspan="1">400/100 mg capsule<br>q12h
x 9Â days</td>
<td class="Toprule" colspan="1" rowspan="1">600 mg qd x 9Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">11,7<span class="Sup">c</span>
</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”<span class="Sup">d</span>
</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 19%<span class="Sup">d</span><br>(â†“Â 36-â†‘Â 3%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 39%<span class="Sup">d</span><br>(3-62%)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Â </td>
<td colspan="1" rowspan="1" valign="top">600/150 mg tablet<br>q12h
x 10 days with<br>efavirenz compared to<br>400/100 mg q12h
alone</td>
<td colspan="1" rowspan="1" valign="top">600 mg qd x 9Â days</td>
<td align="center" colspan="1" rowspan="1" valign="top">23</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†‘Â 36%<span class="Sup">d</span><br>(28-44%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†‘Â 36%<span class="Sup">d</span><br>(28-44%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†‘Â 32%<span class="Sup">d</span><br>(21-44%)</td>
</tr>
<tr valign="top">
<td class="Toprule" colspan="1" rowspan="1">Nelfinavir</td>
<td class="Toprule" colspan="1" rowspan="1">750 mg q8h x 7Â days</td>
<td class="Toprule" colspan="1" rowspan="1">600 mg qd x 7Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">10</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 21%<br>(10-33%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 20%<br>(8-34%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
</tr>
<tr valign="top">
<td colspan="1" rowspan="1">Â Â Â Metabolite<br>Â Â Â Â Â Â AG-1402</td>
<td colspan="3" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">â†“Â 40%<br>(30-48%)</td>
<td align="center" colspan="1" rowspan="1">â†“Â 37%<br>(25-48%)</td>
<td align="center" colspan="1" rowspan="1">â†“Â 43%<br>(21-59%)</td>
</tr>
<tr valign="top">
<td class="Toprule" colspan="1" rowspan="1">Ritonavir</td>
<td class="Toprule" colspan="1" rowspan="1">500 mg q12h x 8Â days</td>
<td class="Toprule" colspan="1" rowspan="1">600 mg qd x 10Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">11</td>
<td class="Toprule" align="left" colspan="3" rowspan="1">Â </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â </td>
<td colspan="3" valign="top">Â Â Â After AM dose</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†‘Â 24%<br>(12-38%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†‘Â 18%<br>(6-33%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†‘Â 42%<br>(9-86%)<span class="Sup">e</span>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â </td>
<td colspan="3" valign="top">Â Â Â After PM dose</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†”</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†”</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†‘Â 24%<br>(3-50%)<span class="Sup">e</span>
</td>
</tr>
<tr valign="top">
<td class="Toprule" colspan="1" rowspan="1">Saquinavir<br>Â Â Â SGC<span class="Sup">f</span>
</td>
<td class="Toprule" colspan="1" rowspan="1">1200 mg q8h x 10Â days</td>
<td class="Toprule" colspan="1" rowspan="1">600 mg qd x 10Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">12</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 50%<br>(28-66%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 62%<br>(45-74%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 56%<br>(16-77%)<span class="Sup">e</span>
</td>
</tr>
<tr valign="top">
<td class="Toprule" colspan="1" rowspan="1">Lamivudine</td>
<td class="Toprule" colspan="1" rowspan="1">150 mg q12h x 14Â days</td>
<td class="Toprule" colspan="1" rowspan="1">600 mg qd x 14Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">9</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 265%<br>(37-873%)</td>
</tr>
<tr valign="top">
<td class="Toprule" colspan="1" rowspan="1">Tenofovir<span class="Sup">g</span>
</td>
<td class="Toprule" colspan="1" rowspan="1">300 mg qd	</td>
<td class="Toprule" colspan="1" rowspan="1">600 mg qd x 14Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">29</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
</tr>
<tr valign="top">
<td class="Toprule" colspan="1" rowspan="1">Zidovudine</td>
<td class="Toprule" colspan="1" rowspan="1">300 mg q12h x 14Â days</td>
<td class="Toprule" colspan="1" rowspan="1">600 mg qd x 14Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">9</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 225%<br>(43-640%)</td>
</tr>
<tr valign="top">
<td class="Toprule" colspan="1" rowspan="1">Maraviroc</td>
<td class="Toprule" colspan="1" rowspan="1">100 mg bid</td>
<td class="Toprule" colspan="1" rowspan="1">600 mg qd</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">12</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 51%<br>(37-62%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 45%<br>(38-51%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 45%<br>(28-57%)</td>
</tr>
<tr valign="top">
<td class="Toprule" colspan="1" rowspan="1">Raltegravir</td>
<td class="Toprule" colspan="1" rowspan="1">400 mg single dose</td>
<td class="Toprule" colspan="1" rowspan="1">600 mg qd</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">9</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 36%<br>(2-59%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 36%<br>(20-48%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 21%<br>(â†“Â 51-â†‘Â 28%)</td>
</tr>
<tr valign="top">
<td class="Toprule" colspan="1" rowspan="1">Boceprevir</td>
<td class="Toprule" colspan="1" rowspan="1">800 mg tid x 6Â days</td>
<td class="Toprule" colspan="1" rowspan="1">600 mg qd x 16Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">NA</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 8%<br>(â†“Â 22-â†‘Â 8%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 19%<br>(11-25%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 44%<br>(26-58%)</td>
</tr>
<tr valign="top">
<td class="Toprule" colspan="1" rowspan="1">Telaprevir</td>
<td class="Toprule" colspan="1" rowspan="1">750 mg q8h x 10Â days</td>
<td class="Toprule" colspan="1" rowspan="1">600 mg qd x 20Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">21</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 9%<br>(â†“Â 18-â†‘Â 2%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 26%<br>(16-35%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 47%<br>(35-56%)</td>
</tr>
<tr valign="top">
<td class="Toprule" colspan="1" rowspan="1">Azithromycin</td>
<td class="Toprule" colspan="1" rowspan="1">600 mg single dose</td>
<td class="Toprule" colspan="1" rowspan="1">400 mg qd x 7Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">14</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 22%<br>(4-42%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">NA</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Clarithromycin</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">500 mg q12h x 7Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">400 mg qd x 7Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">11</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 26%<br>(15-35%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 39%<br>(30-46%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 53%<br>(42-63%)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â 14-OH metabolite</td>
<td align="left" colspan="3" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">â†‘Â 49%<br>(32-69%)</td>
<td align="center" colspan="1" rowspan="1">â†‘Â 34%<br>(18-53%)</td>
<td align="center" colspan="1" rowspan="1">â†‘Â 26%<br>(9-45%)</td>
</tr>
<tr valign="top">
<td class="Toprule" colspan="1" rowspan="1">Fluconazole</td>
<td class="Toprule" colspan="1" rowspan="1">200 mg x 7Â days</td>
<td class="Toprule" colspan="1" rowspan="1">400 mg qd x 7Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">10</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
</tr>
<tr valign="top">
<td class="Toprule" colspan="1" rowspan="1">Itraconazole</td>
<td class="Toprule" colspan="1" rowspan="1">200 mg q12h x 28Â days</td>
<td class="Toprule" colspan="1" rowspan="1">600 mg qd x 14Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">18</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 37%<br>(20-51%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 39%<br>(21-53%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 44%<br>(27-58%)</td>
</tr>
<tr valign="top">
<td colspan="1" rowspan="1">Â Â Â Hydroxy-itraconazole</td>
<td colspan="3" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">â†“Â 35%<br>(12-52%)</td>
<td align="center" colspan="1" rowspan="1">â†“Â 37%<br>(14-55%)</td>
<td align="center" colspan="1" rowspan="1">â†“Â 43%<br>(18-60%)</td>
</tr>
<tr valign="top">
<td class="Toprule" colspan="1" rowspan="1">Posaconazole</td>
<td class="Toprule" colspan="1" rowspan="1">400 mg (oral suspension) bid x 10 and 20Â days</td>
<td class="Toprule" colspan="1" rowspan="1">400 mg qd x 10 and 20Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">11</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 45%<br>(34-53%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 50%<br>(40-57%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">NA</td>
</tr>
<tr valign="top">
<td class="Toprule" colspan="1" rowspan="1">Rifabutin</td>
<td class="Toprule" colspan="1" rowspan="1">300 mg qd x 14Â days</td>
<td class="Toprule" colspan="1" rowspan="1">600 mg qd x 14Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">9</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 32%<br>(15-46%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 38%<br>(28-47%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 45%<br>(31-56%)</td>
</tr>
<tr valign="top">
<td class="Toprule" colspan="1" rowspan="1">Voriconazole</td>
<td class="Toprule" colspan="1" rowspan="1">400 mg po q12h x 1 day, then 200
mg po q12h x 8Â days</td>
<td class="Toprule" colspan="1" rowspan="1">400 mg qd x 9Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">NA</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 61%<span class="Sup">h</span>
</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 77%<span class="Sup">h</span>
</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="left" colspan="1" rowspan="1" valign="top">300 mg po q12h daysÂ 2â€‘7</td>
<td align="left" colspan="1" rowspan="1" valign="top">300 mg qd x 7Â days</td>
<td align="center" colspan="1" rowspan="1" valign="top">	NA</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†“Â 36%<span class="Sup">i</span><br>(21-49%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†“Â 55%<span class="Sup">i</span><br>(45-62%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="left" colspan="1" rowspan="1" valign="top">400 mg po q12h daysÂ 2â€‘7</td>
<td align="left" colspan="1" rowspan="1" valign="top">300 mg qd x 7 days</td>
<td align="center" colspan="1" rowspan="1" valign="top">NA</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†‘Â 23%<span class="Sup">i</span><br>(â†“Â 1-â†‘Â 53%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†“Â 7%<span class="Sup">i</span><br>(â†“Â 23-â†‘Â 13%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Atorvastatin</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">10 mg qd x 4Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 15Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">14</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 14%<br>(1-26%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 43%<br>(34-50%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 69%<br>(49-81%)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â Total active<br>Â Â Â (including<br>Â Â Â metabolites)</td>
<td align="left" colspan="3" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">â†“Â 15%<br>(2-26%)</td>
<td align="center" colspan="1" rowspan="1">â†“Â 32%<br>(21-41%)</td>
<td align="center" colspan="1" rowspan="1">â†“Â 48%<br>(23-64%)</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Pravastatin</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">40 mg qd x 4Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 15Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">13</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 32%<br>(â†“Â 59-â†‘Â 12%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 44%<br>(26-57%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 19%<br>(0-35%)</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Simvastatin</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">40 mg qd x 4Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 15Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">14</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 72%<br>(63-79%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 68%<br>(62-73%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 45%<br>(20-62%)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â Total active<br>Â Â Â (including<br>Â Â Â metabolites)</td>
<td align="left" colspan="3" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">â†“Â 68%<br>(55-78%)</td>
<td align="center" colspan="1" rowspan="1">â†“Â 60%<br>(52-68%)</td>
<td align="center" colspan="1" rowspan="1">NA<span class="Sup">j</span>
</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Carbamazepine</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">200 mg qd x 3 days,
200 mg bid x 3 days, then 400 mg qd x 29Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 14Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">12</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 20%<br>(15-24%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 27%<br>(20-33%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 35%<br>(24-44%)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Epoxide metabolite</td>
<td align="left" colspan="3" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">â†”</td>
<td align="center" colspan="1" rowspan="1">â†”</td>
<td align="center" colspan="1" rowspan="1">â†“Â 13%<br>(â†“Â 30-â†‘Â 7%)</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Cetirizine</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">10 mg single dose</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 10Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">11</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 24%<br>(18-30%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">NA</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Diltiazem</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">240 mg x 21Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 14Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">13</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 60%<br>(50-68%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 69%<br>(55-79%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 63%<br>(44-75%)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â Desacetyl<br>Â Â Â diltiazem</td>
<td align="left" colspan="3" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">â†“Â 64%<br>(57-69%)</td>
<td align="center" colspan="1" rowspan="1">â†“Â 75%<br>(59-84%)</td>
<td align="center" colspan="1" rowspan="1">â†“Â 62%<br>(44-75%)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â N-<br>Â Â Â monodesmethyl<br>Â Â Â diltiazem</td>
<td align="left" colspan="3" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">â†“Â 28%<br>(7-44%)</td>
<td align="center" colspan="1" rowspan="1">â†“Â 37%<br>(17-52%)</td>
<td align="center" colspan="1" rowspan="1">â†“Â 37%<br>(17-52%)</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Ethinyl estradiol/<br>
													Â Â Â Norgestimate</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">0.035Â mg/<br>0.25Â mg x 14Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600Â mg qd x 14Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1"></td>
<td class="Toprule" align="center" colspan="1" rowspan="1"></td>
<td class="Toprule" align="center" colspan="1" rowspan="1"></td>
<td class="Toprule" align="center" colspan="1" rowspan="1"></td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â Ethinyl<br>Â Â Â estradiol</td>
<td align="left" colspan="2" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">21</td>
<td align="center" colspan="1" rowspan="1">â†”</td>
<td align="center" colspan="1" rowspan="1">â†”</td>
<td align="center" colspan="1" rowspan="1">â†”</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â Norelgestromin</td>
<td align="left" colspan="2" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">21</td>
<td align="center" colspan="1" rowspan="1">â†“Â 46%<br>(39-52%)</td>
<td align="center" colspan="1" rowspan="1">â†“Â 64%<br>(62-67%)</td>
<td align="center" colspan="1" rowspan="1">â†“Â 82%<br>(79-85%)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â Levonorgestrel</td>
<td align="left" colspan="2" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">6</td>
<td align="center" colspan="1" rowspan="1">â†“Â 80%<br>(77-83%)</td>
<td align="center" colspan="1" rowspan="1">â†“Â 83%<br>(79-87%)</td>
<td align="center" colspan="1" rowspan="1">â†“Â 86%<br>(80-90%)</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Lorazepam</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">2 mg single dose</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 10Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">12</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 16%<br>(2-32%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">NA</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Methadone</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">Stable<br>maintenance
35-<br>100 mg daily</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 14-21Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">11</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 45%<br>(25-59%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 52%<br>(33-66%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">NA</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Bupropion</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">150 mg single dose<br>(sustained-release)</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 14 days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">13</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 34%<br>(21-47%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 55%<br>(48-62%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">NA</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â Hydroxy-<br>Â Â Â bupropion</td>
<td align="left" colspan="3" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">â†‘Â 50%<br>(20-80%)</td>
<td align="center" colspan="1" rowspan="1">â†”</td>
<td align="center" colspan="1" rowspan="1">NA</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1" valign="top">Paroxetine</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">20 mg qd x 14Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 14Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">16</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
</tr>
<tr class="Last" valign="top">
<td class="Botrule Toprule" align="left" colspan="1" rowspan="1">Sertraline</td>
<td class="Botrule Toprule" align="left" colspan="1" rowspan="1">50 mg qd x 14Â days</td>
<td class="Botrule Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 14Â days</td>
<td class="Botrule Toprule" align="center" colspan="1" rowspan="1">13</td>
<td class="Botrule Toprule" align="center" colspan="1" rowspan="1">â†“Â 29%<br>(15-40%)</td>
<td class="Botrule Toprule" align="center" colspan="1" rowspan="1">â†“Â 39%<br>(27-50%)</td>
<td class="Botrule Toprule" align="center" colspan="1" rowspan="1">â†“Â 46%<br>(31-58%)</td>
</tr>
</tbody>
</table>
<a name="table9"></a><table width="100%">
<caption><span>Table 9:	Effect of Coadministered Drug on Efavirenz Plasma C<span class="Sub">max</span>,
AUC, and C<span class="Sub">min</span></span></caption>
<col width="14%">
<col width="16%">
<col width="16%">
<col width="9%">
<col width="15%">
<col width="15%">
<col width="15%">
<thead>
<tr class="First">
<th class="Toprule" colspan="4">Â </th>
<th class="Botrule Toprule" align="center" colspan="3" valign="bottom"><span class="Bold">Efavirenz<br>(mean % change)</span></th>
</tr>
<tr class="Last">
<th class="Botrule" align="left" valign="bottom"><span class="Bold">Coadministered Drug</span></th>
<th class="Botrule" align="center" valign="bottom"><span class="Bold">Dose</span></th>
<th class="Botrule" align="center" valign="bottom"><span class="Bold">Efavirenz Dose</span></th>
<th class="Botrule" align="center" valign="bottom"><span class="Bold">Number of Subjects</span></th>
<th class="Botrule" align="center" valign="bottom"><span class="Bold">C<span class="Sub">max</span><br>(90% CI)</span></th>
<th class="Botrule" align="center" valign="bottom"><span class="Bold">AUC<br>(90% CI)</span></th>
<th class="Botrule" align="center" valign="bottom"><span class="Bold">C<span class="Sub">min</span><br>(90% CI)</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="7">â†‘ Indicates increaseÂ Â Â  â†“ Indicates decreaseÂ Â Â â†”  Indicates no change or a mean increase or decrease of &lt;10%.</td></tr>
<tr><td colspan="7">
<span class="Sup">a</span>Â Â Parallel-group design; n for
efavirenz + lopinavir/ritonavir, n for efavirenz alone.</td></tr>
<tr><td colspan="7">
<span class="Sup">b</span>Â Â 95% CI.</td></tr>
<tr><td colspan="7">
<span class="Sup">c</span>Â Â Soft Gelatin Capsule.</td></tr>
<tr><td colspan="7">
<span class="Sup">d</span>Â Â Tenofovir disoproxil fumarate.</td></tr>
<tr><td colspan="7">
<span class="Sup">e</span>Â Â 90% CI not available.</td></tr>
<tr><td colspan="7">
<span class="Sup">f</span>Â Â Relative to steady-state administration
of efavirenz (600 mg once daily for 9 days).</td></tr>
<tr class="Last"><td align="left" colspan="7">NA = not available.</td></tr>
</tfoot>
<tbody>
<tr class="First" valign="top">
<td align="left" colspan="1" rowspan="1">Indinavir</td>
<td align="left" colspan="1" rowspan="1">800 mg q8h x 14Â days</td>
<td align="left" colspan="1" rowspan="1">200 mg qd x 14Â days</td>
<td align="center" colspan="1" rowspan="1">11</td>
<td align="center" colspan="1" rowspan="1">â†”</td>
<td align="center" colspan="1" rowspan="1">â†”</td>
<td align="center" colspan="1" rowspan="1">â†”</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Lopinavir/<br>Â Â Â ritonavir</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">400/100 mg q12h x
9Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 9Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">11,12<span class="Sup">a</span>
</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 16%<br>(â†“Â 38-â†‘Â 15%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 16%<br>(â†“Â 42-â†‘Â 20%)</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Nelfinavir</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">750 mg q8h x 7Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 7Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">10</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 12%<br>(â†“Â 32-â†‘Â 13%)<span class="Sup">b</span>
</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 12%<br>(â†“Â 35-â†‘Â 18%)<span class="Sup">b</span>
</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 21%<br>(â†“Â 53-â†‘Â 33%)</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Ritonavir</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">500 mg q12h x 8Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 10Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">9</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 14%<br>(4-26%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 21%<br>(10-34%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 25%<br>(7-46%)<span class="Sup">b</span>
</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Saquinavir<br>Â Â Â SGC<span class="Sup">c</span>
</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">1200 mg q8h x 10Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 10Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">13</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 13%<br>(5-20%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 12%<br>(4-19%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 14%<br>(2-24%)<span class="Sup">b</span>
</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Tenofovir<span class="Sup">d</span>
</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">300 mg qd</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 14Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">30</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Boceprevir</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">800 mg tid x 6Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 16Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">NA</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 11%<br>(2-20%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 20%<br>(15-26%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">NA</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Telaprevir</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">750 mg q8h x 10Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 20Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">21</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 16%<br>(7-24%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 7%<br>(2-13%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 2%<br>(â†“Â 6-â†‘Â 2%)</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="2">Telaprevir, coadministered with tenofovir disoproxil fumarate (TDF)</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">1125 mg q8h x 7Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg efavirenz/300 mg TDF qd x 7Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">15</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 24%<br>(15-32%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 18%<br>(10-26%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 10%<br>(â†“Â 19-â†‘Â 1%)</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">1500 mg q12h x 7Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg efavirenz/300 mg TDF qd x 7Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">16</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 20%<br>(14-26%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 15%<br>(9-21%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 11%<br>(4-18%)</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Azithromycin</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg single dose</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">400 mg qd x 7Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">14</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Clarithromycin</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">500 mg q12h x 7Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">400 mg qd x 7Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">12</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 11%<br>(3-19%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Fluconazole</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">200 mg x<br>7Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">400 mg qd x 7Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">10</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 16%<br>(6-26%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 22%<br>(5-41%)</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Itraconazole</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">200 mg q12h x 14Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 28Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">16</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Rifabutin</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">300 mg qd x 14Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 14Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">11</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 12%<br>(â†“Â 24-â†‘Â 1%)</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Rifampin</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg x<br>7Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 7Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">12</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 20%<br>(11-28%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 26%<br>(15-36%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 32%<br>(15-46%)</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Voriconazole</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">400 mg po q12h<br>x
1Â day, then 200Â mg po q12h<br>x 8Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">400 mg qd x 9Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">NA</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 38%<span class="Sup">e</span>
</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 44%<span class="Sup">e</span>
</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â </td>
<td align="left" colspan="1" rowspan="1" valign="top">300 mg po q12h days
2-7</td>
<td align="left" colspan="1" rowspan="1" valign="top">300 mg qd x 7Â days</td>
<td align="center" colspan="1" rowspan="1" valign="top">NA</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†“Â 14%<span class="Sup">f</span><br>(7-21%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†”<span class="Sup">f</span>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â </td>
<td align="left" colspan="1" rowspan="1" valign="top">400 mg po q12h days
2-7</td>
<td align="left" colspan="1" rowspan="1" valign="top">300 mg qd x 7Â days</td>
<td align="center" colspan="1" rowspan="1" valign="top">NA</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†”<span class="Sup">f</span>
</td>
<td align="center" colspan="1" rowspan="1" valign="top">â†‘Â 17%<span class="Sup">f</span><br>(6-29%)</td>
<td align="center" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Atorvastatin</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">10 mg qd x<br>4Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 15Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">14</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Pravastatin</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">40 mg qd x<br>4Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 15Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">11</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Simvastatin</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">40 mg qd x<br>4Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 15Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">14</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 12%<br>(â†“Â 28-â†‘Â 8%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“Â 12%<br>(â†“Â 25-â†‘Â 3%)</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">AluminumÂ hydroxide
400 mg, magnesium hydroxide 400 mg, plus simethicone 40 mg</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">30 mL single dose</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">400 mg single dose</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">17</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">NA</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Carbamazepine</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">200 mg qd x 3Â days,
200Â mg<br>bid x 3Â days, then 400Â mg qd x 15Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 35Â days	</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">14</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“ 21%<br>(15-26%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“ 36%<br>(32-40%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†“ 47%<br>(41-53%)</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Cetirizine</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">10 mg single dose</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 10Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">11</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Diltiazem</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">240 mg x<br>14 days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 28 days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">12</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 16%<br>(6-26%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 11%<br>(5-18%)</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†‘Â 13%<br>(1-26%)</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Famotidine</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">40 mg single dose</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">400 mg single dose</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">17</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">NA</td>
</tr>
<tr valign="top">
<td class="Toprule" align="left" colspan="1" rowspan="1">Paroxetine</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">20 mg qd x 14Â days</td>
<td class="Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 14Â days</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">12</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">â†”</td>
</tr>
<tr class="Last" valign="top">
<td class="Botrule Toprule" align="left" colspan="1" rowspan="1">Sertraline</td>
<td class="Botrule Toprule" align="left" colspan="1" rowspan="1">50 mg qd x
14Â days</td>
<td class="Botrule Toprule" align="left" colspan="1" rowspan="1">600 mg qd x 14Â days</td>
<td class="Botrule Toprule" align="center" colspan="1" rowspan="1">13</td>
<td class="Botrule Toprule" align="center" colspan="1" rowspan="1">â†‘ 11%<br>(6-16%)</td>
<td class="Botrule Toprule" align="center" colspan="1" rowspan="1">â†”</td>
<td class="Botrule Toprule" align="center" colspan="1" rowspan="1">â†”</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="Section_12.4"></a><a name="section-11.3"></a><p></p>
<h2>12.4     Microbiology</h2>
<div class="Section" data-sectionCode="49489-8">
<a name="Section_12.4.1"></a><a name="section-11.3.1"></a><p></p>
<h3 class="Bold">Mechanism of Action</h3>
<p class="First">Efavirenz (EFV) is an NNRTI of HIV-1.
EFV activity is mediated predominantly by noncompetitive inhibition of HIV-1
reverse transcriptase (RT). HIV-2 RT and human cellular DNA polymerases Î±, Î², Î³, and Î´ are not inhibited by EFV. </p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="Section_12.4.2"></a><a name="section-11.3.2"></a><p></p>
<h3 class="Bold">Antiviral Activity in Cell Culture</h3>
<p class="First">The concentration of EFV inhibiting
replication of wild-type laboratory adapted <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> and clinical isolates
in cell culture by 90-95% (EC<span class="Sub">90-95</span>) ranged from 1.7
to 25 nM in lymphoblastoid cell lines, peripheral blood mononuclear cells
(PBMCs), and macrophage/monocyte cultures. EFV demonstrated antiviral activity
against clade B and most non-clade B isolates (subtypes A, AE, AG, C, D, F,
G, J, N), but had reduced antiviral activity against group O viruses. EFV
demonstrated additive antiviral activity without cytotoxicity against HIV-1
in cell culture when combined with the NNRTIs delavirdine (DLV) and nevirapine
(NVP), NRTIs (abacavir, didanosine, emtricitabine, lamivudine [LAM], stavudine,
tenofovir, zalcitabine, zidovudine [ZDV]), PIs (amprenavir, indinavir [IDV],
lopinavir, nelfinavir, ritonavir, saquinavir), and the fusion inhibitor enfuvirtide.
EFV demonstrated additive to antagonistic antiviral activity in cell culture
with atazanavir. EFV was not antagonistic with adefovir, used for the treatment
of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or ribavirin, used in combination with interferon
for the treatment of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> C virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="Section_12.4.3"></a><a name="section-11.3.3"></a><p></p>
<h3 class="Bold">Resistance</h3>
<div class="Section" data-sectionCode="49489-8">
<a name="Section_12.4.3.1"></a><a name="section-11.3.3.1"></a><p></p>
<h4 class="Bold">In cell culture</h4>
<p class="First">In cell culture, HIV-1 isolates with
reduced susceptibility to EFV (&gt;380-fold increase in EC<span class="Sub">90</span> value)
emerged rapidly in the presence of drug. Genotypic characterization of these
viruses identified single amino acid substitutions L100I or V179D, double
substitutions L100I/V108I, and triple substitutions L100I/V179D/Y181C in
RT.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="Section_12.4.3.2"></a><a name="section-11.3.3.2"></a><p></p>
<h4 class="Bold">Clinical studies</h4>
<p class="First">Clinical isolates with reduced susceptibility
in cell culture to EFV have been obtained. One or more RT substitutions at
amino acid positions 98, 100, 101, 103, 106, 108, 188, 190, 225, and 227 were
observed in patients failing treatment with EFV in combination with IDV, or
with ZDV plus LAM. The mutation K103N was the most frequently observed. Long-term
resistance surveillance (average 52 weeks, range 4-106 weeks) analyzed 28
matching baseline and virologic failure isolates. Sixty-one percent (17/28)
of these failure isolates had decreased EFV susceptibility in cell culture
with a median 88-fold change in EFV susceptibility (EC<span class="Sub">50</span> value)
from reference. The most frequent NNRTI substitution to develop in these patient
isolates was K103N (54%). Other NNRTI substitutions that developed included
L100I (7%), K101E/Q/R (14%), V108I (11%), G190S/T/A (7%), P225H (18%), and
M230I/L (11%).</p>
</div>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="Section_12.4.4"></a><a name="section-11.3.4"></a><p></p>
<h3 class="Bold">Cross-Resistance</h3>
<p class="First">Cross-resistance among NNRTIs has been
observed. Clinical isolates previously characterized as EFV-resistant were
also phenotypically resistant in cell culture to DLV and NVP compared to baseline.
DLV- and/or NVP-resistant clinical viral isolates with NNRTI resistance-associated
substitutions (A98G, L100I, K101E/P, K103N/S, V106A, Y181X, Y188X, G190X,
P225H, F227L, or M230L) showed reduced susceptibility to EFV in cell culture.
Greater than 90% of NRTI-resistant clinical isolates tested in cell culture
retained susceptibility to EFV.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13     NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1     Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1.1"></a><a name="section-12.1.1"></a><p></p>
<h3 class="Bold">Carcinogenesis</h3>
<p class="First">Long-term carcinogenicity studies in mice and rats were carried out with efavirenz. Mice were dosed with 0,
25, 75, 150, or 300 mg/kg/day for 2 years. Incidences of <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> and carcinomas and pulmonary alveolar/bronchiolar <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> were increased above background in females. No increases in tumor incidence above background were seen in males. There was no NOAEL in females established for this study because tumor findings occurred at all doses. AUC at the NOAEL (150 mg/kg) in the males was approximately 0.9 times that in humans at the recommended clinical dose. In the rat study, no increases in tumor incidence were observed at doses up to 100 mg/kg/day, for which AUCs were 0.1 (males) or 0.2 (females) times those in humans at the recommended clinical dose.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1.2"></a><a name="section-12.1.2"></a><p></p>
<h3 class="Bold">Mutagenesis</h3>
<p class="First">Efavirenz tested negative in a battery of <span class="Italics">in
vitro </span> and <span class="Italics">in vivo </span> genotoxicity assays. These included bacterial
mutation assays in <span class="Italics">S. typhimurium  </span> and  <span class="Italics">E. coli</span>,
mammalian mutation assays in Chinese hamster ovary cells, chromosome aberration assays in human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> or Chinese hamster ovary cells, and an <span class="Italics">in vivo </span> mouse bone marrow micronucleus assay.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1.3"></a><a name="section-12.1.3"></a><p></p>
<h3 class="Bold">Impairment of Fertility</h3>
<p class="First">Efavirenz did not impair mating or fertility of male or female rats, and did not affect sperm of treated male rats. The reproductive performance of offspring born to female rats given efavirenz was not affected. The AUCs at the NOAEL values in male (200 mg/kg) and female (100 mg/kg) rats were approximately â‰¤0.15 times that in humans at the recommended clinical dose. 
								</p>
</div>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="Section_13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2     Animal Toxicology</h2>
<p class="First">Nonsustained <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> were observed in 6 of 20 monkeys receiving efavirenz at doses yielding plasma AUC values
4- to 13-fold greater than those in humans given the recommended dose [see <span class="Italics">Warnings and Precautions <a href="#Section_5.9">(5.9)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14     CLINICAL STUDIES</h1>
<p class="First"><span class="Bold">Study 006</span>, a randomized, open-label trial, compared SUSTIVA (600 mg once daily) + zidovudine (ZDV, 300 mg q12h) + lamivudine (LAM, 150 mg q12h) or SUSTIVA (600 mg once daily) + indinavir (IDV, 1000 mg q8h) with indinavir (800 mg q8h) + zidovudine (300 mg q12h) + lamivudine (150 mg q12h). Twelve hundred sixty-six patients (mean age 36.5 years [range 18-81], 60% Caucasian, 83% male) were enrolled. All patients were efavirenz-, lamivudine-, NNRTI-, and PI-naive at study entry. The median baseline CD4+ cell count was 320 cells/mm<span class="Sup">3</span> and the median baseline HIV-1 RNA level was 4.8 log<span class="Sub">10</span> copies/mL. Treatment outcomes with standard assay (assay limit 400 copies/mL) through 48 and 168 weeks are shown in <a href="#table10"> Table 10</a>. Plasma HIV RNA levels were quantified with standard (assay limit 400 copies/mL) and ultrasensitive (assay limit 50 copies/mL) versions of the AMPLICOR HIV-1 MONITOR assay. During the study, version 1.5 of the assay was introduced in Europe to enhance detection of non-clade B virus.</p>
<a name="table10"></a><table width="100%">
<caption><span>Table 10:	Outcomes of Randomized Treatment Through 48 and 168 Weeks,
Study 006</span></caption>
<col width="28%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="11%">
<col width="11%">
<thead>
<tr class="First">
<td class="Toprule" align="left" colspan="1" rowspan="1">Â </td>
<td class="Botrule Toprule" align="center" colspan="2" rowspan="1" valign="bottom">SUSTIVA
+ ZDV<br>+ LAM<br>(n=422)</td>
<td class="Botrule Toprule" align="center" colspan="2" rowspan="1" valign="bottom"> SUSTIVA
+ IDV<br>(n=429)</td>
<td class="Botrule Toprule" align="center" colspan="2" rowspan="1" valign="bottom"> IDV
+ ZDV + LAM<br>(n=415)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" colspan="1" rowspan="1">Outcome</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">Week 48</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">Week 168</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">Week 48</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">Week 168</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">Week 48</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">Week 168</td>
</tr>
</thead>
<tfoot>
<tr class="First"><td colspan="7" rowspan="1">
<span class="Sup">a</span>Â Â Patients achieved
and maintained confirmed HIV-1 RNA &lt;400 copies/mL through Week 48 or Week
168.</td></tr>
<tr><td colspan="7" rowspan="1">
<span class="Sup">b</span>Â Â Includes patients
who rebounded, patients who were on study at Week 48 and failed to achieve
confirmed HIV-1 RNA &lt;400 copies/mL at time of discontinuation, and patients
who discontinued due to lack of efficacy.</td></tr>
<tr class="Last"><td colspan="7" rowspan="1">
<span class="Sup">c</span>Â Â Includes consent
withdrawn, lost to follow-up, noncompliance, never treated, missing data,
protocol violation, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, and other reasons. Patients with HIV-1 RNA levels &lt;400 copies/mL who chose not to continue in the voluntary extension phases
of the study were censored at date of last dose of study medication.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left" colspan="1" rowspan="1">Responder<span class="Sup">a</span>
</td>
<td align="center" colspan="1" rowspan="1">69%</td>
<td align="center" colspan="1" rowspan="1">48%</td>
<td align="center" colspan="1" rowspan="1">57%</td>
<td align="center" colspan="1" rowspan="1">40%</td>
<td align="center" colspan="1" rowspan="1">50%</td>
<td align="center" colspan="1" rowspan="1">29%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Virologic failure<span class="Sup">b</span>
</td>
<td align="center" colspan="1" rowspan="1">6%</td>
<td align="center" colspan="1" rowspan="1">12%</td>
<td align="center" colspan="1" rowspan="1">15%</td>
<td align="center" colspan="1" rowspan="1">20%</td>
<td align="center" colspan="1" rowspan="1">13%</td>
<td align="center" colspan="1" rowspan="1">19%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Discontinued for adverse events</td>
<td align="center" colspan="1" rowspan="1">7%</td>
<td align="center" colspan="1" rowspan="1">8%</td>
<td align="center" colspan="1" rowspan="1">6%</td>
<td align="center" colspan="1" rowspan="1">8%</td>
<td align="center" colspan="1" rowspan="1">16%</td>
<td align="center" colspan="1" rowspan="1">20%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Discontinued for other reasons<span class="Sup">c</span>
</td>
<td align="center" colspan="1" rowspan="1">17%</td>
<td align="center" colspan="1" rowspan="1">31%</td>
<td align="center" colspan="1" rowspan="1">22%</td>
<td align="center" colspan="1" rowspan="1">32%</td>
<td align="center" colspan="1" rowspan="1">21%</td>
<td align="center" colspan="1" rowspan="1">32%</td>
</tr>
<tr><td class="Toprule" align="left" colspan="7" rowspan="1">CD4+ cell count (cells/mm<span class="Sup">3</span>)</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Observed subjects (n)</td>
<td align="center" colspan="1" rowspan="1">(279)</td>
<td align="center" colspan="1" rowspan="1">(205)</td>
<td align="center" colspan="1" rowspan="1">(256)</td>
<td align="center" colspan="1" rowspan="1">(158)</td>
<td align="center" colspan="1" rowspan="1">(228)</td>
<td align="center" colspan="1" rowspan="1">(129)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" colspan="1" rowspan="1">Â Â Â Mean change
from<br>Â Â Â baseline</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">190</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">329</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">191</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">319</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">180</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">329</td>
</tr>
</tbody>
</table>
<p>For patients treated with SUSTIVA + zidovudine + lamivudine,
SUSTIVA + indinavir, or indinavir + zidovudine + lamivudine, the percentage
of responders with HIV-1 RNA &lt;50Â copies/mL was 65%, 50%, and 45%, respectively,
through 48 weeks, and 43%, 31%, and 23%, respectively, through 168 weeks.
A Kaplan-Meier analysis of time to loss of virologic response (HIV RNA &lt;400
copies/mL) suggests that both the trends of virologic response and differences
in response continue through 4 years.</p>
<p><span class="Bold">ACTG
364</span> is a randomized, double-blind, placebo-controlled, 48-week study
in NRTI-experienced patients who had completed two prior ACTG studies. One-hundred
ninety-six patients (mean age 41 years [range 18-76], 74% Caucasian, 88% male)
received NRTIs in combination with SUSTIVA (efavirenz) (600 mg once daily),
or nelfinavir (NFV, 750 mg three times daily), or SUSTIVA (600 mg once daily)
+ nelfinavir in a randomized, double-blinded manner. The mean baseline CD4+
cell count was 389 cells/mm<span class="Sup">3</span>  and mean baseline
HIV-1 RNA level was 8130 copies/mL. Upon entry into the study, all patients
were assigned a new open-label NRTI regimen, which was dependent on their
previous NRTI treatment experience. There was no significant difference in
the mean CD4+ cell count among treatment groups; the overall mean increase
was approximately 100 cells at 48 weeks among patients who continued on study
regimens. Treatment outcomes are shown in <a href="#table11">Table 11</a>. Plasma HIV RNA levels
were quantified with the AMPLICOR HIV-1 MONITOR assay using a lower limit
of quantification of 500 copies/mL.</p>
<a name="table11"></a><table width="100%">
<caption><span>Table 11:	Outcomes of Randomized Treatment Through 48 Weeks, Study
ACTG 364*</span></caption>
<col width="31%">
<col width="23%">
<col width="23%">
<col width="23%">
<thead><tr class="First Last" valign="bottom">
<td class="Botrule Toprule" align="left" colspan="1" rowspan="1">Outcome</td>
<td class="Botrule Toprule" align="center" colspan="1" rowspan="1">SUSTIVA +
NFV +<br>NRTIs<br>(n=65)</td>
<td class="Botrule Toprule" align="center" colspan="1" rowspan="1">SUSTIVA + NRTIs<br>(n=65)</td>
<td class="Botrule Toprule" align="center" colspan="1" rowspan="1">NFV + NRTIs<br>(n=66)</td>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="4" rowspan="1">*Â Â For some patients, Week 56 data
were used to confirm the status at Week 48.</td></tr>
<tr><td colspan="4" rowspan="1">
<span class="Sup">a</span>Â Â Subjects achieved
virologic response (two consecutive viral loads &lt;500 copies/mL) and maintained
it through Week 48.</td></tr>
<tr><td colspan="4" rowspan="1">
<span class="Sup">b</span>Â Â Includes viral rebound
and failure to achieve confirmed &lt;500 copies/mL by Week 48.</td></tr>
<tr><td colspan="4" rowspan="1">
<span class="Sup">c</span>Â Â See <span class="Italics">Adverse
Reactions <a href="#Section_6.1">(6.1)</a></span> for a safety profile
of these regimens.</td></tr>
<tr class="Last"><td colspan="4" rowspan="1">
<span class="Sup">d</span>Â Â Includes loss to
follow-up, consent withdrawn, noncompliance.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left" colspan="1" rowspan="1">HIV-1 RNA &lt;500 copies/mL<span class="Sup">a</span>
</td>
<td align="center" colspan="1" rowspan="1">71%</td>
<td align="center" colspan="1" rowspan="1">63%</td>
<td align="center" colspan="1" rowspan="1">41%</td>
</tr>
<tr>
<td class="Toprule" align="left" colspan="1" rowspan="1">HIV-1 RNA â‰¥500 copies/mL<span class="Sup">b</span>
</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">17%</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">34%</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">54%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CDC Category C Event</td>
<td align="center" colspan="1" rowspan="1">2%</td>
<td align="center" colspan="1" rowspan="1">0%</td>
<td align="center" colspan="1" rowspan="1">0%</td>
</tr>
<tr>
<td class="Toprule" align="left" colspan="1" rowspan="1">Discontinuations
for adverse events<span class="Sup">c</span>
</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">3%</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">3%</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">5%</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" colspan="1" rowspan="1">Discontinuations
for other reasons<span class="Sup">d</span>
</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">8%</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">0%</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">0%</td>
</tr>
</tbody>
</table>
<p>A Kaplan-Meier analysis of time to treatment failure
through 72 weeks demonstrates a longer duration of virologic suppression (HIV
RNA &lt;500 copies/mL) in the SUSTIVA-containing treatment arms.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-14"></a><p></p>
<h1>16     HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16.1"></a><a name="section-14.1"></a><p></p>
<h2>16.1     Capsules</h2>
<p class="First">SUSTIVA<span class="Sup">Â®</span> (efavirenz)
capsules are available as follows:</p>
<p><span class="Italics">Capsules
200 mg</span> are gold color, reverse printed with â€œSUSTIVAâ€? on the body and imprinted â€œ200 mgâ€? on the cap.</p>
<p></p>
<p><span class="Italics">Capsules 50
mg</span> are gold color and white, printed with â€œSUSTIVAâ€? on the gold color
cap and reverse printed â€œ50 mgâ€? on the white body.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16.2"></a><a name="section-14.2"></a><p></p>
<h2>16.2     Tablets</h2>
<p class="First">SUSTIVA<span class="Sup">Â®</span> (efavirenz) tablets are available
as follows:</p>
<p><span class="Italics">Tablets 600 mg</span> are
yellow, capsular-shaped, film-coated tablets, with â€œSUSTIVAâ€? printed on both
sides.</p>
<p>Â Â Â Â Â Â Bottles of 30Â Â Â Â Â Â NDC 54868-4668-0</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="Section_16.3"></a><a name="section-14.3"></a><p></p>
<h2>16.3     Storage</h2>
<p class="First">SUSTIVA capsules and SUSTIVA tablets
should be stored at 25Â° C (77Â° F); excursions permitted to 15Â°â€“30Â° C (59Â°â€“86Â°
F) [see USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-15"></a><p></p>
<h1>17     PATIENT COUNSELING INFORMATION</h1>
<p class="First">See <span class="Italics">FDA-approved patient labeling (Patient Information)</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1     Drug Interactions</h2>
<p class="First">A statement to patients and healthcare
providers is included on the productâ€™s bottle labels:<br><span class="Italics">ALERT: Find
out about medicines that should NOT be taken with SUSTIVA.</span></p>
<p>SUSTIVA may interact with some drugs; therefore, patients should
be advised to report to their doctor the use of any other prescription, nonprescription
medication, or herbal products, particularly St. Johnâ€™s wort.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2     General Information for Patients</h2>
<p class="First">Patients should be informed that SUSTIVA is not a cure for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and patients may continue to experience
illnesses associated with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. Patients should remain under the care of a physician while taking SUSTIVA.</p>
<p>Patients should be advised to avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to others.</p>
<ul class="Disc">
<li><span class="Bold">Do not share needles or other injection equipment.</span></li>
<li><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span></li>
<li>
<span class="Bold">Do not have any kind of sex without protection.</span> Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</li>
<li>
<span class="Bold">Do not breast-feed.</span> It is not known if SUSTIVA can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV-1 should not breast-feed because HIV-1 can be passed to the baby in breast milk.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.3"></a><a name="section-15.3"></a><p></p>
<h2>17.3     Dosing Instructions</h2>
<p class="First">Patients should be advised to take SUSTIVA
every day as prescribed. SUSTIVA must always be used in combination with other
antiretroviral drugs. Patients should be advised to take SUSTIVA on an empty
stomach, preferably at bedtime. Taking SUSTIVA with food increases efavirenz
concentrations and may increase the frequency of adverse reactions. Dosing
at bedtime may improve the tolerability of nervous system symptoms [see <span class="Italics">Dosage
and Administration <a href="#Section_2">(2) </a></span> and <span class="Italics">Adverse
Reactions <a href="#Section_6.1">(6.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.4"></a><a name="section-15.4"></a><p></p>
<h2>17.4     Nervous System Symptoms</h2>
<p class="First">Patients should be informed that central
nervous system symptoms (NSS) including <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, impaired concentration,
<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, and <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span> are commonly reported during the first weeks
of therapy with SUSTIVA [see <span class="Italics">Warnings and Precautions <a href="#Section_5.5">(5.5)</a></span>].
Dosing at bedtime may improve the tolerability of these symptoms, which are
likely to improve with continued therapy. Patients should be alerted to the
potential for additive effects when SUSTIVA is used concomitantly with alcohol
or psychoactive drugs. Patients should be instructed that if they experience
NSS they should avoid potentially hazardous tasks such as driving or operating
machinery.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.5"></a><a name="section-15.5"></a><p></p>
<h2>17.5     <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">Psychiatric Symptoms</span></h2>
<p class="First">Patients should be informed that serious
<span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span> including severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span>, aggressive
behavior, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusions</span>, <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>, and <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>-like symptoms have been reported
in patients receiving SUSTIVA [see <span class="Italics">Warnings and Precautions <a href="#Section_5.4">(5.4)</a></span>]. If they experience severe
psychiatric adverse experiences they should seek immediate medical evaluation.
Patients should be advised to inform their physician of any history of mental
illness or <span class="product-label-link" type="condition" conceptid="4279309" conceptname="Substance abuse">substance abuse</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.6"></a><a name="section-15.6"></a><p></p>
<h2>17.6     <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></h2>
<p class="First">Patients should be informed that a
common side effect is <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> [see <span class="Italics">Warnings and Precautions <a href="#Section_5.7">(5.7)</a></span>]. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rashes</span> usually go away without any change in treatment. However,
since <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> may be serious, patients should be advised to contact their physician
promptly if <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.7"></a><a name="section-15.7"></a><p></p>
<h2>17.7     Reproductive Risk Potential</h2>
<p class="First">Women receiving SUSTIVA should be
instructed to avoid pregnancy [see <span class="Italics">Warnings and Precautions <a href="#Section_5.6">(5.6)</a></span>]. A reliable form of barrier
contraception must always be used in combination with other methods of contraception,
including oral or other hormonal contraception. Because of the long half-life
of efavirenz, use of adequate contraceptive measures for 12 weeks after discontinuation
of SUSTIVA is recommended. Women should be advised to notify their physician
if they become pregnant or plan to become pregnant while taking SUSTIVA. If
this drug is used during the first trimester of pregnancy, or if the patient
becomes pregnant while taking this drug, she should be apprised of the potential
harm to the fetus.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.8"></a><a name="section-15.8"></a><p></p>
<h2>17.8     Fat Redistribution</h2>
<p class="First">Patients should be informed that redistribution
or accumulation of body fat may occur in patients receiving antiretroviral
therapy and that the cause and long-term health effects of these conditions
are not known [see <span class="Italics">Warnings and Precautions <a href="#Section_5.12">(5.12)</a></span>].</p>
<p></p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="Section_18"></a><a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Patient Information</span></p>
<p><span class="Bold">SUSTIVA</span><span class="Sup">Â®</span><span class="Bold"><span class="Sub"> (sus-TEE-vah)</span></span></p>
<p><span class="Bold">[efavirenz </span> (eh-FAH-vih-rehnz)<span class="Bold">]</span></p>
<p><span class="Bold">capsules and tablets</span></p>
<p><span class="Bold">ALERT:
 Find out about medicines that should NOT be taken with SUSTIVA.</span></p>
<p>Please also read the section â€œ<span class="Bold">MEDICINES YOU SHOULD NOT
TAKE WITH SUSTIVA</span>.â€?
						</p>
<p>Read this information
before you start taking SUSTIVA. Read it again each time you refill your prescription,
in case there is any new information. This leaflet provides a summary about
SUSTIVA and does not include everything there is to know about your medicine.
This information is not meant to take the place of talking with your doctor.</p>
<p><span class="Bold">What is SUSTIVA?</span></p>
<p>SUSTIVA
is a medicine used in combination with other medicines to help treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>
with Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus type 1 (HIV-1), the virus that causes AIDS
(<span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immune deficiency syndrome</span>). SUSTIVA is a type of anti-HIV drug
called a â€œnon-nucleoside reverse transcriptase inhibitorâ€? (NNRTI). NNRTIs
are not used in the treatment of Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus type 2 (HIV-2)
<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>SUSTIVA works by lowering the amount
of HIV-1 in the blood (viral load). SUSTIVA must be taken with other anti-HIV
medicines. When taken with other anti-HIV medicines, SUSTIVA has been shown
to reduce viral load and increase the number of CD4+ cells, a type of immune
cell in blood. SUSTIVA may not have these effects in every patient.</p>
<p>SUSTIVA does not cure HIV or AIDS and you may continue to experience illnesses associated with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. You should remain under the care of a doctor when using SUSTIVA.</p>
<p>Avoid doing things that can spread HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<ul class="Disc">
<li><span class="Bold">Do not share needles or other injection equipment.</span></li>
<li><span class="Bold">Do not share personal items that can have blood or body fluids on them, like toothbrushes and razor blades.</span></li>
<li>
<span class="Bold">Do not have any kind of sex without protection.</span> Always practice safe sex by using a latex or polyurethane condom to lower the chance of sexual contact with semen, vaginal secretions, or blood.</li>
</ul>
<p><span class="Bold">What are the possible side effects of SUSTIVA?</span></p>
<p><span class="Bold">Serious psychiatric problems.</span> A small number of
patients experience severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, strange thoughts, or angry behavior
while taking SUSTIVA. Some patients have thoughts of <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> and a few have
actually committed <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>. These problems tend to occur more often in patients
who have had mental illness. Contact your doctor right away if you think you
are having these <span class="product-label-link" type="condition" conceptid="4294810" conceptname="Psychiatric symptom">psychiatric symptoms</span>, so your doctor can decide if you should
continue to take SUSTIVA (efavirenz).</p>
<p><span class="Bold">Common
side effects.</span> Many patients have <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, trouble sleeping, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>,
trouble concentrating, and/or unusual dreams during treatment with SUSTIVA.
These side effects may be reduced if you take SUSTIVA at bedtime on an empty
stomach. They also tend to go away after you have taken the medicine for a
few weeks. If you have these common side effects, such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, it does
not mean that you will also have serious psychiatric problems, such as severe
<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, strange thoughts, or angry behavior. Tell your doctor right away
if any of these side effects continue or if they bother you. It is possible
that these symptoms may be more severe if SUSTIVA is used with alcohol or
mood altering (street) drugs.</p>
<p>If you are dizzy,
have trouble concentrating, or are drowsy, avoid activities that may be dangerous,
such as driving or operating machinery.</p>
<p><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> is
common. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rashes</span> usually go away without any change in treatment. In a small
number of patients, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> may be serious. If you develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, call your
doctor right away. <span class="Bold"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> may be a serious problem in some children.</span> Tell
your childâ€™s doctor right away if you notice <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or any other side effects
while your child is taking SUSTIVA.</p>
<p>Other common
side effects include <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. Some
patients taking SUSTIVA have experienced increased levels of lipids (<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>
and triglycerides) in the blood.</p>
<p><span class="Bold">Changes in
body fat.</span> Changes in body fat develop in some patients taking anti-HIV
medicine. These changes may include an increased amount of fat in the upper
back and neck (â€œbuffalo humpâ€?), in the breasts, and around the trunk. Loss
of fat from the legs, arms, and face may also happen. The cause and long-term
health effects of these fat changes are not known.</p>
<p><span class="Bold">Liver problems. </span> Some patients taking SUSTIVA have experienced serious liver problems including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> resulting in transplantation or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Most of these serious side effects occurred in patients with a <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span> such as <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, but there have also been a few reports in patients without any existing liver disease.
								</p>
<p>Tell
your doctor or healthcare provider if you notice any side effects while taking
SUSTIVA. </p>
<p>Contact your doctor before stopping SUSTIVA
because of side effects or for any other reason.</p>
<p>This
is not a complete list of side effects possible with SUSTIVA. Ask your doctor
or pharmacist for a more complete list of side effects of SUSTIVA and all
the medicines you will take.</p>
<p><span class="Bold">How should I
take SUSTIVA?</span></p>
<p><span class="Bold">General Information</span></p>
<ul class="Disc">
<li>You should take SUSTIVA on an empty stomach, preferably at bedtime.</li>
<li>Swallow SUSTIVA with water.</li>
<li>Taking SUSTIVA with food increases the amount of medicine in your
body, which may increase the frequency of side effects.</li>
<li>Taking SUSTIVA at bedtime may make some side effects less bothersome.</li>
<li>SUSTIVA must be taken in combination with other anti-HIV medicines.
If you take only SUSTIVA, the medicine may stop working.</li>
<li>Do not miss a dose of SUSTIVA. If you forget to take SUSTIVA, take
the missed dose right away, unless it is almost time for your next dose. Do
not double the next dose. Carry on with your regular dosing schedule. If you
need help in planning the best times to take your medicine, ask your doctor
or pharmacist. </li>
<li>Take the exact amount of SUSTIVA your doctor prescribes. Never change
the dose on your own. Do not stop this medicine unless your doctor tells you
to stop.</li>
<li>If you believe you took more than the prescribed amount of SUSTIVA,
contact your local Poison Control Center or emergency room right away.</li>
<li>Tell your doctor if you start any new medicine or change how you
take old ones. Your doses may need adjustment.</li>
<li>When your SUSTIVA supply starts to run low, get more from your doctor
or pharmacy. This is very important because the amount of virus in your blood
may increase if the medicine is stopped for even a short time. The virus may
develop resistance to SUSTIVA and become harder to treat.</li>
<li>Your doctor may want to do blood tests to check for certain side
effects while you take SUSTIVA (efavirenz).</li>
</ul>
<p><span class="Bold"> Capsules</span></p>
<ul class="Disc"><li>The dose of SUSTIVA capsules for adults is 600 mg (three 200-mg
capsules, taken together) once a day by mouth. The dose of SUSTIVA for children
may be lower (see â€œ<span class="Bold">Can children take SUSTIVA?</span>â€?).</li></ul>
<p><span class="Bold">Tablets</span></p>
<ul class="Disc"><li>The dose of SUSTIVA tablets for adults is 600 mg (one tablet) once
a day by mouth.</li></ul>
<p><span class="Bold">Can children take SUSTIVA?</span></p>
<p>Yes, children who are able to swallow capsules can take SUSTIVA.
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> may be a serious problem in some children. Tell your childâ€™s doctor right
away if you notice <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or any other side effects while your child is taking
SUSTIVA. The dose of SUSTIVA for children may be lower than the dose for adults.
Capsules containing lower doses of SUSTIVA are available. Your childâ€™s doctor
will determine the right dose based on your childâ€™s weight.</p>
<p><span class="Bold">Who should not take SUSTIVA?</span></p>
<p><span class="Bold">Do
not take SUSTIVA if you are allergic</span> to the active ingredient, efavirenz,
or to any of the inactive ingredients. Your doctor and pharmacist have a list
of the inactive ingredients.</p>
<p><span class="Bold">What should I
avoid while taking SUSTIVA?</span></p>
<ul class="Disc">
<li>
<span class="Bold">Women should not become pregnant while taking SUSTIVA and
for 12 weeks after stopping it.</span> Serious <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> have been seen
in the offspring of animals and women treated with SUSTIVA during pregnancy.
It is not known whether SUSTIVA caused these defects. <span class="Bold">Tell your doctor
right away if you are pregnant.</span> Also talk with your doctor if you want
to become pregnant.</li>
<li>Women should not rely only on hormone-based birth control, such
as pills, injections, or implants, because SUSTIVA may make these contraceptives
ineffective. Women must use a reliable form of barrier contraception, such
as a condom or diaphragm, even if they also use other methods of birth control.
SUSTIVA may remain in your blood for a time after therapy is stopped. Therefore,
you should continue to use contraceptive measures for 12 weeks after you stop
taking SUSTIVA.</li>
<li>
<span class="Bold">Do not breast-feed if you are taking SUSTIVA.</span> It is not known if SUSTIVA can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV-1 should not breast-feed because HIV-1 can be passed to the baby in the breast milk. Talk with your doctor if you are breast-feeding. You may need to stop breast-feeding or use a different medicine.</li>
<li>Taking SUSTIVA with alcohol or other medicines causing similar side effects as SUSTIVA, such as <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, may increase those side effects.</li>
<li>Do not take any other medicines without checking with your doctor. These medicines include prescription and nonprescription medicines and herbal
products, especially St. Johnâ€™s wort <span class="Italics">(Hypericum perforatum)</span>.</li>
</ul>
<p><span class="Bold">Before using SUSTIVA, tell your doctor if you</span></p>
<ul class="Disc">
<li>
<span class="Bold">have problems with your liver or have <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.</span> Your
doctor may want to do tests to check your liver while you take SUSTIVA or may switch you to another medicine.</li>
<li><span class="Bold">have ever had mental illness or are using drugs or alcohol.</span></li>
<li>
<span class="Bold">have ever had <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or are taking medicine for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></span> [for
example, Dilantin (phenytoin), Tegretol (carbamazepine), or phenobarbital].
Your doctor may want to switch you to another medicine or check drug levels
in your blood from time to time.</li>
</ul>
<p><span class="Bold">What important information should I know about
taking other medicines with SUSTIVA?</span></p>
<p><span class="Bold">SUSTIVA
may change the effect of other medicines, including ones for HIV, and cause
serious side effects.</span> Your doctor may change your other medicines or
change their doses. Other medicines, including herbal products, may affect
SUSTIVA. For this reason, <span class="Bold">it is very important to</span>:</p>
<ul class="Disc">
<li>let all your doctors and pharmacists know that you take SUSTIVA.</li>
<li>tell your doctors and pharmacists about all medicines you take.
This includes those you buy over-the-counter and herbal or natural remedies.</li>
</ul>
<p>Bring all your prescription and nonprescription medicines
as well as any herbal remedies that you are taking when you see a doctor,
or make a list of their names, how much you take, and how often you take them.
This will give your doctor a complete picture of the medicines you use. Then
he or she can decide the best approach for your situation.</p>
<p>Taking
SUSTIVA with St. Johnâ€™s wort <span class="Italics">(Hypericum perforatum)</span>, an herbal
product sold as a dietary supplement, or products containing St. Johnâ€™s wort
is not recommended. Talk with your doctor if you are taking or are planning
to take St. Johnâ€™s wort. Taking St. Johnâ€™s wort may decrease SUSTIVA levels
and lead to increased viral load and possible resistance to SUSTIVA or cross-resistance
to other anti-HIV drugs.</p>
<p><span class="Bold">MEDICINES YOU SHOULD
NOT TAKE WITH SUSTIVA</span></p>
<p>The following medicines
may cause serious and life-threatening side effects when taken with SUSTIVA.
You should not take any of these medicines while taking SUSTIVA: </p>
<ul class="Disc">
<li>Vascor (bepridil)</li>
<li>Propulsid (cisapride)</li>
<li>Versed (midazolam)</li>
<li>Orap (pimozide)</li>
<li>Halcion (triazolam)</li>
<li>Ergot medications (for example, Wigraine and Cafergot)</li>
</ul>
<p>The following medicine should not be taken with SUSTIVA
since it contains efavirenz, the active ingredient in SUSTIVA:</p>
<ul class="Disc"><li>ATRIPLA (efavirenz, emtricitabine, tenofovir disoproxil fumarate)</li></ul>
<p><span class="Bold">The following medicines may need to be replaced
with another medicine when taken with SUSTIVA:</span></p>
<ul class="Disc">
<li>Fortovase, Invirase (saquinavir)</li>
<li>Biaxin (clarithromycin)</li>
<li>Carbatrol, Tegretol (carbamazepine)</li>
<li>Noxafil (posaconazole)</li>
<li>Sporanox (itraconazole)</li>
<li>REYATAZ (atazanavir sulfate), if this is not the first time you are receiving treatment for your <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span></li>
<li>Victrelis (boceprevir)</li>
</ul>
<p><span class="Bold">The following medicines may require a change in
the dose of either SUSTIVA or the other medicine:</span></p>
<ul class="Disc">
<li>Calcium channel blockers such as Cardizem or Tiazac (diltiazem),
Covera HS or Isoptin SR (verapamil), and others.</li>
<li>The <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering medicines Lipitor (atorvastatin), PRAVACHOL
(pravastatin sodium), and Zocor (simvastatin).</li>
<li>Crixivan (indinavir)</li>
<li>Kaletra (lopinavir/ritonavir)</li>
<li>Methadone</li>
<li>Mycobutin (rifabutin)</li>
<li>REYATAZ (atazanavir sulfate). If you are taking SUSTIVA and REYATAZ,
you should also be taking Norvir (ritonavir).</li>
<li>Rifadin (rifampin) or the rifampin-containing medicines Rifamate
and Rifater.</li>
<li>Selzentry (maraviroc)</li>
<li>Vfend (voriconazole) and SUSTIVA must not be taken together at standard
doses.  Some doses of voriconazole can be taken at the same time as a lower
dose of SUSTIVA, but you must check with your doctor first.</li>
<li>Zoloft (sertraline)</li>
<li>Wellbutrin, Wellbutrin SR, Wellbutrin XL, or Zyban (bupropion)</li>
<li>The immunosuppressant medicines cyclosporine (Gengraf, Neoral, Sandimmune, and others), Prograf (tacrolimus), or Rapamune (sirolimus).</li>
</ul>
<p><span class="Bold">These are not all the medicines that may cause
problems if you take SUSTIVA. Be sure to tell your doctor about all medicines
that you take.</span></p>
<p><span class="Bold">General advice about
SUSTIVA:</span></p>
<p><span class="Bold">Medicines are sometimes prescribed
for conditions that are not mentioned in patient information leaflets. Do
not use SUSTIVA for a condition for which it was not prescribed. Do not give
SUSTIVA to other people, even if they have the same symptoms you have. It
may harm them.</span></p>
<p>Keep SUSTIVA at room temperature
(77Â° F) in the bottle given to you by your pharmacist. The temperature can
range from 59Â° to 86Â° F. </p>
<p>Keep SUSTIVA out
of the reach of children.</p>
<p>This leaflet summarizes
the most important information about SUSTIVA. If you would like more information,
talk with your doctor. You can ask your pharmacist or doctor for the full
prescribing information about SUSTIVA, or you can visit the SUSTIVA website
at <span class="Italics">www.sustiva.com</span> or call 1-800-321-1335.</p>
<p>__________________</p>
<p><span class="Sub">SUSTIVA is a registered
trademark of Bristol-Myers Squibb Pharma Company, ATRIPLA is a trademark of
Bristol-Myers Squibb &amp; Gilead Sciences, LLC, PRAVACHOL is a registered
trademark of ER Squibb &amp; Sons, LLC, and REYATAZ is a registered trademark
of Bristol-Myers Squibb Company. Other brands listed are the trademarks of
their respective owners.</span></p>
<p></p>
<p>Distributed by:</p>
<p>Bristol-Myers
Squibb  Company<br>Princeton, NJ 08543 USA</p>
<p>SUSTIVA<span class="Sup">Â®</span> (efavirenz) capsules made in India.</p>
<p><span class="Sub">Â© Bristol-Myers Squibb Company 2012</span></p>
<p>1262274A8<br>510230013IN09<br>Rev August 2012</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.1"></a><p></p>
<p class="First">Distributed by:<br>Physicians Total Care, Inc.<br>Tulsa, OKÂ Â Â Â Â  74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First">NDC 54868-4668-0 Â Â Â Â  30 Tablets</p>
<p><span class="Bold">SUSTIVA</span><span class="Sup">Â®</span>Â Â Â Â Â  Rx only
									<br><span class="Bold">(efavirenz) tablets</span></p>
<p>600 mg</p>
<p>Each tablet contains 600 mg of efavirenz.<br><span class="Bold">DOSAGE:</span> For dosage and full prescribing<br>information, read accompanying package<br>insert.<br><span class="Bold">Note to pharmacist: Do not cover<br> ALERT box with pharmacy label.</span></p>
<p><span class="Bold">ALERT: Find out about medicines that<br>should NOT be taken with SUSTIVA</span><span class="Sup">Â®</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 600 mg Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=04b5c345-c446-43a4-83f0-509bc287e10b&amp;name=4668.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SUSTIVAÂ 		
					</strong><br><span class="contentTableReg">efavirenz tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4668(NDC:0056-0510)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>efavirenz</strong> (efavirenz) </td>
<td class="formItem">efavirenz</td>
<td class="formItem">600Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hydroxypropyl cellulose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carnauba wax</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">SUSTIVA;SUSTIVA</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4668-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021360</td>
<td class="formItem">10/11/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel(54868-4668)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0e9a5a51-266a-490c-90fd-f553a5d378de</div>
<div>Set id: 04b5c345-c446-43a4-83f0-509bc287e10b</div>
<div>Version: 2</div>
<div>Effective Time: 20130102</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
